

Randomized, Double-Masked, Sham-Controlled Trial of Age-related Macular Degeneration: PIER Study Year 1

American Journal of Ophthalmology

145, 239-248.e5

DOI: [10.1016/j.ajo.2007.10.004](https://doi.org/10.1016/j.ajo.2007.10.004)

Citation Report

#	ARTICLE	IF	CITATIONS
1	A supplement to: "A new confidence interval for the difference between two binomial proportions of paired data". Journal of Statistical Planning and Inference, 2007, 137, 357-358.	0.4	18
2	Current status of anti-vascular endothelial growth factor therapy in Europe. Japanese Journal of Ophthalmology, 2008, 52, 433-439.	0.9	26
3	Rapamycin reduces VEGF expression in retinal pigment epithelium (RPE) and inhibits RPE-induced sprouting angiogenesis in vitro. FEBS Letters, 2008, 582, 3097-3102.	1.3	61
4	Age-Related Macular Degeneration. New England Journal of Medicine, 2008, 358, 2606-2617.	13.9	1,345
5	Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. , 2008, , CD005139.		60
6	Is There Tachyphylaxis to Intravitreal Anti-Vascular Endothelial Growth Factor Pharmacotherapy in Age-Related Macular Degeneration?. Ophthalmology, 2008, 115, 2199-2205.	2.5	198
7	Computerized Model of Cost-Utility Analysis for Treatment of Age-Related Macular Degeneration. Ophthalmology, 2008, 115, 2192-2198.	2.5	34
8	Anti-Vascular Endothelial Growth Factor Pharmacotherapy for Age-Related Macular Degeneration. Ophthalmology, 2008, 115, 1837-1846.	2.5	132
9	Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration. Clinical Therapeutics, 2008, 30, 2436-2451.	1.1	33
10	Shall we use Avastin [®] or Lucentis [®] for ocular neovascularization?. Acta Ophthalmologica, 2008, 86, 352-355.	0.6	6
11	Pharmacotherapy of age-related macular degeneration. Expert Opinion on Pharmacotherapy, 2008, 9, 3045-3052.	0.9	10
12	Computer-Based Visual Evaluation as a Screening Tool after Intravitreal Injections of Vascular Endothelial Growth Factor Inhibitors. Ophthalmologica, 2008, 222, 364-368.	1.0	8
13	Ranibizumab for neovascular age-related macular degeneration. American Journal of Health-System Pharmacy, 2008, 65, 1805-1814.	0.5	25
14	PKC Inhibition and Diabetic Complications. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2008, 2, 72-78.	0.7	1
15	COMBINATION PHOTODYNAMIC THERAPY AND INTRAVITREAL RANIBIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN A NORTH INDIAN POPULATION. Retina, 2008, 28, 1296-1301.	1.0	4
16	The cost of vision for vitreoretinal interventions. Current Opinion in Ophthalmology, 2008, 19, 195-201.	1.3	2
17	COMBINATION PHOTODYNAMIC THERAPY AND INTRAVITREAL RANIBIZUMAB IN NEOVASCULAR AMD IN A NORTH INDIAN POPULATION. Retina, 2008, 28, 1132-1137.	1.0	10
18	Treatment of neovascular age-related macular degeneration: Current therapies. Clinical Ophthalmology, 2009, 3, 175.	0.9	28

#	ARTICLE	IF	CITATIONS
19	Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?. <i>Clinical Interventions in Aging</i> , 2009, 4, 457.	1.3	21
20	Intravitreal ranibizumab and bevacizumab for the treatment of nonsubfoveal choroidal neovascularization in age-related macular degeneration. <i>Arquivos Brasileiros De Oftalmologia</i> , 2009, 72, 677-681.	0.2	3
21	Macular Thickness Measurements in Healthy Eyes Using Six Different Optical Coherence Tomography Instruments. , 2009, 50, 3432.		393
22	Pharmacotherapy of Retinal Diseases with Ranibizumab. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2371.	0.1	1
23	Twelve-month short-term safety and visual-acuity results from a multicentre prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degeneration. <i>British Journal of Ophthalmology</i> , 2009, 93, 305-309.	2.1	70
24	Large Subretinal Haemorrhage following Change from Intravitreal Bevacizumab to Ranibizumab. <i>Ophthalmologica</i> , 2009, 223, 279-282.	1.0	22
25	Current Trends in Age-Related Macular Degeneration. <i>Postgraduate Medicine</i> , 2009, 121, 136-140.	0.9	0
28	VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1573-1580.	1.9	119
29	Quantitative Subanalysis of Cystoid Spaces and Outer Nuclear Layer Using Optical Coherence Tomography in Age-Related Macular Degeneration. , 2009, 50, 3366.		52
30	Comparative Study of Intravitreal Bevacizumab (Avastin) versus Ranibizumab (Lucentis) in the Treatment of Neovascular Age-Related Macular Degeneration. <i>Ophthalmologica</i> , 2009, 223, 370-375.	1.0	60
31	Age-related maculopathy â€“ Linking aetiology and pathophysiological changes to the ischaemia hypothesis. <i>Progress in Retinal and Eye Research</i> , 2009, 28, 63-86.	7.3	116
32	Intravitreal ranibizumab (LucentisÂ®) for the treatment of myopic choroidal neovascularization. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2009, 247, 311-318.	1.0	65
33	Intravitreal ranibizumab (LucentisÂ®) in the treatment of retinal angiomatous proliferation (RAP). <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2009, 247, 1165-1171.	1.0	52
35	One-year results of intravitreal ranibizumab for neovascular age-related macular degeneration and clinical responses of various subgroups. <i>Japanese Journal of Ophthalmology</i> , 2009, 53, 389-395.	0.9	35
37	New paradigms in the treatment of wet AMD: the impact of anti-VEGF therapy. <i>Eye</i> , 2009, 23, S1-S7.	1.1	26
38	Ranibizumab treatment for neovascular age-related macular degeneration: from randomized trials to clinical practice. <i>Eye</i> , 2009, 23, 1633-1640.	1.1	19
39	Choroidal neovascularization in age-related macular degeneration depends on vascular endothelial growth factor, but vascular endothelial growth factor should not be the promising treatment target. <i>Bioscience Hypotheses</i> , 2009, 2, 88-91.	0.2	1
40	Lamellar Keratoplasty. <i>Ophthalmology</i> , 2009, 116, 362-363.	2.5	0

#	ARTICLE	IF	CITATIONS
41	Cerebrovascular Accidents in Ranibizumab. <i>Ophthalmology</i> , 2009, 116, 362-362.e1.	2.5	110
42	Economic Implications of Current Age-Related Macular Degeneration Treatments. <i>Ophthalmology</i> , 2009, 116, 481-487.	2.5	27
43	Comparison of Spectral-Domain versus Time-Domain Optical Coherence Tomography in Management of Age-Related Macular Degeneration with Ranibizumab. <i>Ophthalmology</i> , 2009, 116, 947-955.	2.5	94
44	High-speed Ultrahigh Resolution Optical Coherence Tomography before and after Ranibizumab for Age-related Macular Degeneration. <i>Ophthalmology</i> , 2009, 116, 956-963.	2.5	42
45	Verteporfin Photodynamic Therapy Combined With Intravitreal Bevacizumab for Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2009, 116, 747-755.e1.	2.5	83
46	A Phase IIIb Study to Evaluate the Safety of Ranibizumab in Subjects with Neovascular Age-related Macular Degeneration. <i>Ophthalmology</i> , 2009, 116, 1731-1739.	2.5	305
47	Evaluation of Injection Frequency and Visual Acuity Outcomes for Ranibizumab Monotherapy in Exudative Age-related Macular Degeneration. <i>Ophthalmology</i> , 2009, 116, 1740-1747.	2.5	124
48	Antiangiogenic Approaches to Age-Related Macular Degeneration Today. <i>Ophthalmology</i> , 2009, 116, S15-S23.	2.5	112
49	Outcome Measures to Assess Efficacy of Treatments for Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2009, 116, S8-S14.	2.5	6
50	Effects of Ranibizumab in Patients with Subfoveal Choroidal Neovascularization Attributable to Age-related Macular Degeneration. <i>American Journal of Ophthalmology</i> , 2009, 147, 831-837.	1.7	100
51	A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study. <i>American Journal of Ophthalmology</i> , 2009, 148, 43-58.e1.	1.7	818
52	Bilateral Simultaneous Intravitreal Injections in the Office Setting. <i>American Journal of Ophthalmology</i> , 2009, 148, 66-69.e1.	1.7	62
53	Results of One-Year's Treatment with Ranibizumab for Exudative Age-related Macular Degeneration in a Clinical Setting. <i>American Journal of Ophthalmology</i> , 2009, 148, 409-413.e1.	1.7	138
54	The As-Needed Treatment Strategy for Choroidal Neovascularization: A Feedback-Based Treatment System. <i>American Journal of Ophthalmology</i> , 2009, 148, 1-3.	1.7	64
55	Bevacizumab vs Ranibizumab for Age-Related Macular Degeneration: Early Results of a Prospective Double-Masked, Randomized Clinical Trial. <i>American Journal of Ophthalmology</i> , 2009, 148, 875-882.e1.	1.7	66
56	Photoreceptor status after anti-vascular endothelial growth factor therapy in exudative age-related macular degeneration. <i>British Journal of Ophthalmology</i> , 2009, 93, 622-626.	2.1	58
57	Emerging Pharmacologic Therapies for Wet Age-Related Macular Degeneration. <i>Ophthalmologica</i> , 2009, 223, 401-410.	1.0	68
58	VEGF inhibitors for the treatment of neovascular age-related macular degeneration. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 637-646.	1.9	53

#	ARTICLE	IF	CITATIONS
59	Efficacy of intravitreal bevacizumab (Avastin [®]) therapy for early and advanced neovascular age-related macular degeneration. <i>Acta Ophthalmologica</i> , 2009, 87, 611-617.	0.6	24
60	Effect of intravitreal bevacizumab (Avastin [®]) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results. <i>Acta Ophthalmologica</i> , 2010, 88, 594-600.	0.6	25
61	The treatment of wet AMD in Canada: access to therapy (policy review). <i>Canadian Journal of Ophthalmology</i> , 2009, 44, 548-556.	0.4	3
62	ONE-YEAR FOLLOW-UP OF COMBINED CUSTOMIZED THERAPY. PHOTODYNAMIC THERAPY AND BEVACIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2009, 29, 13-19.	1.0	14
63	VERTEPORFIN COMBINATION REGIMENS IN THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2009, 29, 133-148.	1.0	30
64	FIRST VERSUS SECOND EYE INTRAVITREAL RANIBIZUMAB THERAPY FOR WET AMD. <i>Retina</i> , 2009, 29, 325-328.	1.0	14
65	EFFECT OF RANIBIZUMAB RETREATMENT FREQUENCY ON NEUROSENSORY RETINAL VOLUME IN NEOVASCULAR AMD. <i>Retina</i> , 2009, 29, 592-600.	1.0	13
66	INTRAVITREAL INJECTION OF THERAPEUTIC AGENTS. <i>Retina</i> , 2009, 29, 875-912.	1.0	215
67	COMBINATION THERAPY FOR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2009, 29, S45-S48.	1.0	16
68	MACULAR HEMORRHAGE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AFTER STABILIZATION WITH ANTIANGIOGENIC THERAPY. <i>Retina</i> , 2009, 29, 1074-1079.	1.0	17
69	“TREAT AND EXTEND” DOSING OF INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR TYPE 3 NEOVASCULARIZATION/RETINAL ANGIOMATOUS PROLIFERATION. <i>Retina</i> , 2009, 29, 1424-1431.	1.0	187
70	Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration. <i>Current Opinion in Ophthalmology</i> , 2009, 20, 223-225.	1.3	40
72	Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. <i>Current Opinion in Ophthalmology</i> , 2009, 20, 158-165.	1.3	110
73	Knowledge discovery in ophthalmology: analysis of wet form of age-related macular degeneration treatment outcomes. <i>Proceedings of SPIE</i> , 2009, , .	0.8	0
74	Anti-VEGF Therapy in Proliferative Diabetic Retinopathy. <i>International Ophthalmology Clinics</i> , 2009, 49, 95-107.	0.3	30
75	Screening Older Adults for Impaired Visual Acuity: A Review of the Evidence for the U.S. Preventive Services Task Force. <i>Annals of Internal Medicine</i> , 2009, 151, 44.	2.0	41
77	Age-Related Macular Degeneration: A Guide for the Primary Care Physician. <i>Journal of the National Medical Association</i> , 2009, 101, 134-138.	0.6	10
78	CLINICAL CHARACTERISTICS OF ENDOPHTHALMITIS AFTER AN INJECTION OF INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR. <i>Retina</i> , 2010, 30, 1051-1057.	1.0	50

#	ARTICLE	IF	CITATIONS
79	DOSING REGIMEN AND THE FREQUENCY OF MACULAR HEMORRHAGES IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH RANIBIZUMAB. <i>Retina</i> , 2010, 30, 1376-1385.	1.0	13
80	HEMORRHAGIC RECURRENCE OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION NOT PREDICTED BY SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY. <i>Retinal Cases and Brief Reports</i> , 2010, 4, 1-4.	0.3	1
82	A COST-EFFECTIVENESS ANALYSIS OF THREE TREATMENTS FOR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2010, 30, 212-221.	1.0	23
83	COMPARISON OF TWO DOSES OF INTRAVITREAL BEVACIZUMAB AS PRIMARY TREATMENT FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION. <i>Retina</i> , 2010, 30, 1002-1011.	1.0	42
84	Do We Need a New Classification for Choroidal Neovascularization in Age-Related Macular Degeneration?. <i>Retina</i> , 2010, 30, 1333-1349.	1.0	365
85	Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review. <i>Current Opinion in Ophthalmology</i> , 2010, 21, 218-226.	1.3	45
86	Complications of intravitreal injections. <i>Current Opinion in Ophthalmology</i> , 2010, 21, 178-183.	1.3	241
87	SAFETY EVALUATION OF REPEATED INTRAVITREAL INJECTIONS OF BEVACIZUMAB AND RANIBIZUMAB IN RABBIT EYES. <i>Retina</i> , 2010, 30, 671-681.	1.0	34
88	LONG-TERM FOLLOW-UP FOR TYPE 1 (SUBRETINAL PIGMENT EPITHELIUM) NEOVASCULARIZATION USING A MODIFIED "TREAT AND EXTEND" DOSING REGIMEN OF INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. <i>Retina</i> , 2010, 30, 1368-1375.	1.0	105
89	Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2010, 248, 943-956.	1.0	26
90	Photodynamic therapy alone versus combined with intravitreal bevacizumab for neovascular age-related macular degeneration without polypoidal choroidal vasculopathy in Japanese patients. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2010, 248, 931-936.	1.0	12
91	Bevacizumab treatment for choroidal neovascularization due to age-related macular degeneration in Japanese patients. <i>Japanese Journal of Ophthalmology</i> , 2010, 54, 124-128.	0.9	7
92	Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab. <i>Japanese Journal of Ophthalmology</i> , 2010, 54, 310-319.	0.9	39
93	Treatment of age-related macular degeneration: Beyond VEGF. <i>Japanese Journal of Ophthalmology</i> , 2010, 54, 523-528.	0.9	29
94	Predictors of response after intravitreal bevacizumab injection for neovascular age-related macular degeneration. <i>Japanese Journal of Ophthalmology</i> , 2010, 54, 571-577.	0.9	29
95	Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degeneration. <i>International Ophthalmology</i> , 2010, 30, 261-266.	0.6	18
96	Optical coherence tomography-based intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. <i>International Ophthalmology</i> , 2010, 30, 267-270.	0.6	9
97	Intravitreal pegaptanib sodium for choroidal neovascularisation secondary to age-related macular degeneration: Pan-European experience. <i>Eye</i> , 2010, 24, 793-798.	1.1	10

#	ARTICLE	IF	CITATIONS
98	Neovascular age-related macular degeneration: decision making and optimal management. <i>Eye</i> , 2010, 24, 497-505.	1.1	25
99	Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. <i>Eye</i> , 2010, 24, 1708-1715.	1.1	71
100	TIMP-2 modulates VEGFR-2 phosphorylation and enhances phosphodiesterase activity in endothelial cells. <i>Laboratory Investigation</i> , 2010, 90, 374-382.	1.7	30
101	Intravitreal Crystalline Drug Delivery for Intraocular Proliferation Diseases. , 2010, 51, 474.		28
103	Antiangiogenic drugs in the management of ocular diseases: Focus on antivascular endothelial growth factor. <i>Clinical Ophthalmology</i> , 2010, 4, 275.	0.9	16
104	Identifying Early Recurrence of Choroidal Neovascularization during Treatment with Ranibizumab using C-Scan. <i>European Journal of Ophthalmology</i> , 2010, 20, 559-564.	0.7	2
105	Use of nepafenac (Nevanac®) in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections. <i>Clinical Ophthalmology</i> , 2010, 4, 1249.	0.9	16
106	Effects on Choroidal Neovascularization after Anti-VEGF Upload Using Intravitreal Ranibizumab, as Determined by Spectral Domain-Optical Coherence Tomography. , 2010, 51, 1671.		46
107	A protocol for the retina surgeon’s safe initial intravitreal injections. <i>Clinical Ophthalmology</i> , 2010, 4, 1279.	0.9	35
108	Comparative Review of Ranibizumab versus Bevacizumab in the Treatment of Neovascular Age-related Macular Degeneration. <i>Clinical Medicine Insights Therapeutics</i> , 2010, 2, CMT.S2226.	0.4	0
109	Lucentis® using Visudyne® study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration. <i>Clinical Ophthalmology</i> , 2010, 4, 1073.	0.9	18
110	The Effects of a Flexible Visual Acuity"Driven Ranibizumab Treatment Regimen in Age-Related Macular Degeneration: Outcomes of a Drug and Disease Model. , 2010, 51, 405.		68
111	INTERPRETATION OF FDA REGISTRATION CLINICAL TRIALS IN RETINA:CAN WE USE THEM TO GUIDE CLINICAL PRACTICE?. <i>Evidence-Based Ophthalmology</i> , 2010, 11, 137-138.	0.0	0
112	Update on combination therapy in wet age-related macular degeneration. <i>Expert Review of Ophthalmology</i> , 2010, 5, 681-688.	0.3	1
113	Combination therapy with verteporfin and anti-VEGF agents in neovascular age-related macular degeneration: where do we stand?. <i>British Journal of Ophthalmology</i> , 2010, 94, 143-145.	2.1	17
114	Alternative anti-VEGF treatment regimens in exudative age-related macular degeneration. <i>Expert Review of Ophthalmology</i> , 2010, 5, 799-809.	0.3	0
115	Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study). <i>Diabetes Care</i> , 2010, 33, 2399-2405.	4.3	656
116	Small Dense Particles in the Retina Observable by Spectral-Domain Optical Coherence Tomography in Age-Related Macular Degeneration. , 2010, 51, 5965.		78

#	ARTICLE	IF	CITATIONS
117	VEGF-targeted therapy and beyond: pharmacotherapy and emerging treatments in age-related macular degeneration. Expert Review of Clinical Pharmacology, 2010, 3, 243-252.	1.3	7
118	Therapeutic monoclonal antibodies and fragments ranibizumab. , 2010, , 226-229.		1
119	Sorafenib prevents human retinal pigment epithelium cells from light-induced overexpression of VEGF, PDGF and PlGF. British Journal of Ophthalmology, 2010, 94, 1533-1539.	2.1	29
120	Antivascular Endothelial Growth Factors in Age-Related Macular Degeneration. Developments in Ophthalmology, 2010, 46, 21-38.	0.1	15
121	Clinical safety of ranibizumab in age-related macular degeneration. Expert Opinion on Drug Safety, 2010, 9, 149-165.	1.0	48
122	Risks of Mortality, Myocardial Infarction, Bleeding, and Stroke Associated With Therapies for Age-Related Macular Degeneration. JAMA Ophthalmology, 2010, 128, 1273.	2.6	181
123	Response to Ranibizumab Therapy in Neovascular AMD – An Evaluation of Good and Bad Responders. Klinische Monatsblätter Für Augenheilkunde, 2010, 227, 244-248.	0.3	26
126	Anti-VEGF agents for age-related macular degeneration. Expert Opinion on Therapeutic Patents, 2010, 20, 103-118.	2.4	31
127	Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. British Journal of Ophthalmology, 2010, 94, 2-13.	2.1	262
128	The effects of nepafenac and amfenac on retinal angiogenesis. Brain Research Bulletin, 2010, 81, 310-319.	1.4	27
129	Agreement of Time-Domain and Spectral-Domain Optical Coherence Tomography with Fluorescein Leakage from Choroidal Neovascularization. Ophthalmology, 2010, 117, 1376-1380.	2.5	63
130	A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology, 2010, 117, 2134-2140.	2.5	264
131	Phase I Study of Subconjunctival Ranibizumab in Patients With Primary Pterygium Undergoing Pterygium Surgery. American Journal of Ophthalmology, 2010, 149, 926-931.e2.	1.7	22
132	Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-Related Macular Degeneration: PIER Study Year 2. American Journal of Ophthalmology, 2010, 150, 315-324.e1.	1.7	301
133	Drugs used in ocular treatment. Side Effects of Drugs Annual, 2010, , 865-877.	0.6	1
134	Bevacizumab versus ranibizumab for the treatment of neovascular age-related macular degeneration. Expert Review of Ophthalmology, 2010, 5, 603-615.	0.3	1
135	Radiation therapy in the treatment of exudative age-related macular degeneration. Expert Review of Ophthalmology, 2011, 6, 323-337.	0.3	1
136	Die altersabhängige Makuladegeneration – eine Übersicht. Zentralblatt Für Arbeitsmedizin, Arbeitsschutz Und Ergonomie, 2011, 61, 270-286.	0.1	1

#	ARTICLE	IF	CITATIONS
137	Cost Effectiveness of Treatments for Wet Age-Related Macular Degeneration. <i>Pharmacoeconomics</i> , 2011, 29, 107-131.	1.7	40
138	A Review of Ranibizumab Clinical Trial Data in Exudative Age-Related Macular Degeneration and How to Translate It into Daily Practice. <i>Ophthalmologica</i> , 2011, 225, 112-119.	1.0	17
140	A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab. <i>Current Medical Research and Opinion</i> , 2011, 27, 1465-1475.	0.9	91
141	Arterial Thromboembolic Events in Patients with Exudative Age-Related Macular Degeneration Treated with Intravitreal Bevacizumab or Ranibizumab. <i>Ophthalmologica</i> , 2011, 225, 211-221.	1.0	51
142	Management of Neovascular AMD. , 2011, , 79-98.		0
143	Review of Ranibizumab Trials for Neovascular Age-Related Macular Degeneration. <i>Seminars in Ophthalmology</i> , 2011, 26, 372-379.	0.8	33
144	Treatment of wet age-related macular degeneration with ranibizumab in clinical practice: Results and prognostic factors. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , 2011, 86, 254-259.	0.1	1
145	Drug Product Development for the Back of the Eye. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2011, , .	0.2	13
146	Endophthalmitis Following Intravitreal Anti-Vascular Endothelial Growth Factor Injections for Neovascular Age-Related Macular Degeneration. <i>Seminars in Ophthalmology</i> , 2011, 26, 139-148.	0.8	21
147	How the Comparison of Age-related Macular Degeneration Treatments Trial Results Will Impact Clinical Care. <i>American Journal of Ophthalmology</i> , 2011, 152, 509-514.	1.7	18
148	Association of ranibizumab (Lucentis®) or bevacizumab (Avastin®) with dexamethasone and triamcinolone acetonide: An in vitro stability assessment. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2011, 78, 271-277.	2.0	22
151	Systemic and Ocular Safety of Intravitreal Anti-VEGF Therapies for Ocular Neovascular Disease. <i>Survey of Ophthalmology</i> , 2011, 56, 95-113.	1.7	257
153	Effects of Vitreomacular Adhesion on Anti-Vascular Endothelial Growth Factor Treatment for Exudative Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2011, 118, 101-110.	2.5	85
154	Ranibizumab for Choroidal Neovascularization Secondary to Causes Other Than Age-Related Macular Degeneration: A Phase I Clinical Trial. <i>Ophthalmology</i> , 2011, 118, 111-118.	2.5	50
155	Characteristics of Patients Losing Vision after 2 Years of Monthly Dosing in the Phase III Ranibizumab Clinical Trials. <i>Ophthalmology</i> , 2011, 118, 523-530.	2.5	228
156	Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE Study. <i>Ophthalmology</i> , 2011, 118, 831-839.	2.5	353
157	Safety and Efficacy of a Flexible Dosing Regimen of Ranibizumab in Neovascular Age-Related Macular Degeneration: The SUSTAIN Study. <i>Ophthalmology</i> , 2011, 118, 663-671.	2.5	366
158	Sustained Benefits from Ranibizumab for Macular Edema Following Branch Retinal Vein Occlusion: 12-Month Outcomes of a Phase III Study. <i>Ophthalmology</i> , 2011, 118, 1594-1602.	2.5	430

#	ARTICLE	IF	CITATIONS
159	The 1-year Results of CLEAR-IT 2, a Phase 2 Study of Vascular Endothelial Growth Factor Trap-Eye Dosed As-needed After 12-week Fixed Dosing. <i>Ophthalmology</i> , 2011, 118, 1098-1106.	2.5	143
160	Incidence of Retinal Pigment Epithelial Tears after Intravitreal Ranibizumab Injection for Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2011, 118, 2447-2452.	2.5	79
161	Long-term efficacy and safety of ranibizumab administered <i>pro re nata</i> in Japanese patients with neovascular age-related macular degeneration in the EXTEND study. <i>Acta Ophthalmologica</i> , 2011, 89, 208-217.	0.6	27
162	Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration. <i>New England Journal of Medicine</i> , 2011, 364, 1897-1908.	13.9	2,355
163	Age-related macular degeneration. <i>Clinical Ophthalmology</i> , 2011, 5, 593.	0.9	9
164	Early Multifocal Electroretinogram Findings during Intravitreal Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration. , 2011, 52, 3446.		11
165	The Role of Spectral-Domain OCT in the Diagnosis and Management of Neovascular Age-Related Macular Degeneration. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2011, 42, S56-66.	0.4	59
166	Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema. <i>Clinical Ophthalmology</i> , 2011, 5, 1303.	0.9	17
167	Fixation Control before and after Treatment for Neovascular Age-Related Macular Degeneration. , 2011, 52, 4208.		32
168	Suppression of Choroidal Neovascularization by Vasohibin-1, a Vascular Endothelium-Derived Angiogenic Inhibitor. , 2011, 52, 3272.		13
169	Remission and Dropout Rate of Anti-VEGF Therapy for Age-Related Macular Degeneration. <i>European Journal of Ophthalmology</i> , 2011, 21, 777-782.	0.7	45
170	Management of Neovascular Age-Related Macular Degeneration in Clinical Practice: Initiation, Maintenance, and Discontinuation of Therapy. <i>Journal of Ophthalmology</i> , 2011, 2011, 1-10.	0.6	5
171	As-Needed Treatment with Ranibizumab 0.5 mg in Patients with Neovascular Age-Related Macular Degeneration. <i>European Journal of Ophthalmology</i> , 2011, 21, 282-289.	0.7	14
172	One-Year Outcomes Using Ranibizumab for Neovascular Age-Related Macular Degeneration: Results of a Prospective and Retrospective Observational Multicentre Study. <i>Journal of Ophthalmology</i> , 2011, 2011, 1-8.	0.6	46
173	ONE-YEAR OUTCOMES OF LESS FREQUENT BEVACIZUMAB IN AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2011, 31, 645-653.	1.0	13
174	AGE-RELATED MACULAR DEGENERATION, ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS, AND SHORT-TERM MORTALITY. <i>Retina</i> , 2011, 31, 1036-1042.	1.0	14
175	Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration. <i>Current Opinion in Ophthalmology</i> , 2011, 22, 152-158.	1.3	34
176	BILATERAL EFFECT OF UNILATERAL RANIBIZUMAB IN PATIENTS WITH UVEITIS-RELATED MACULAR EDEMA. <i>Retina</i> , 2011, 31, 1871-1876.	1.0	36

#	ARTICLE	IF	CITATIONS
177	ONE-YEAR RESULTS OF A FLEXIBLE REGIMEN WITH RANIBIZUMAB THERAPY IN MACULAR DEGENERATION. <i>Retina</i> , 2011, 31, 1261-1267.	1.0	22
178	Preferred therapies for neovascular age-related macular degeneration. <i>Current Opinion in Ophthalmology</i> , 2011, 22, 199-204.	1.3	36
179	Pharmacological Treatments for Neovascular Age-Related Macular Degeneration: Can Mixed Treatment Comparison Meta-Analysis be Useful?. <i>Current Drug Targets</i> , 2011, 12, 212-220.	1.0	5
180	INJECT AND EXTEND DOSING VERSUS DOSING AS NEEDED. <i>Retina</i> , 2011, 31, 26-30.	1.0	143
181	Clinical Evidence of Intravitreal Triamcinolone Acetonide in the Management of Age-Related Macular Degeneration. <i>Current Drug Targets</i> , 2011, 12, 149-172.	1.0	56
182	Combined Treatment Modalities for Age Related Macular Degeneration. <i>Current Drug Targets</i> , 2011, 12, 182-189.	1.0	11
183	Age-related macular degeneration: review of current treatments. <i>Expert Review of Ophthalmology</i> , 2011, 6, 195-201.	0.3	1
184	Anti-VEGF Compounds in the Treatment of Neovascular Age Related Macular Degeneration. <i>Current Drug Targets</i> , 2011, 12, 173-181.	1.0	95
185	Ranibizumab in the treatment of choroidal neovascularisation due to age-related macular degeneration: an optical coherence tomography and multifocal electroretinography study. <i>Australasian journal of optometry</i> , The, 2011, 94, 268-275.	0.6	8
186	Systemic and Kidney Toxicity of Intraocular Administration of Vascular Endothelial Growth Factor Inhibitors. <i>American Journal of Kidney Diseases</i> , 2011, 57, 756-759.	2.1	83
187	Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. <i>Eye</i> , 2011, 25, 661-672.	1.1	110
188	Individual recurrence intervals after anti-VEGF therapy for age-related macular degeneration. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2011, 249, 645-652.	1.0	34
189	Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2011, 249, 633-637.	1.0	66
190	Long-term visual course after anti-VEGF therapy for exudative AMD in clinical practice evaluation of the German reinjection scheme. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2011, 249, 639-644.	1.0	47
191	Results of flexible ranibizumab treatment in age-related macular degeneration and search for parameters with impact on outcome. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2011, 249, 653-662.	1.0	49
192	Characteristics of eyes with secondary loss of visual acuity receiving variable dosing ranibizumab for neovascular age-related macular degeneration. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2011, 249, 1635-1642.	1.0	34
193	Ranibizumab treatment administered as needed for occult and minimally classic neovascular membranes in age-related macular degeneration. <i>Japanese Journal of Ophthalmology</i> , 2011, 55, 123-127.	0.9	6
197	AltersabhÄngige Makuladegeneration. , 2011, , .		3

#	ARTICLE	IF	CITATIONS
200	Estimated Cases of Legal Blindness and Visual Impairment Avoided Using Ranibizumab for Choroidal Neovascularization. <i>JAMA Ophthalmology</i> , 2011, 129, 709-17.	2.6	103
202	Outcome of ranibizumab treatment in neovascular age related macula degeneration in eyes with baseline visual acuity better than 6/12. <i>Eye</i> , 2011, 25, 1617-1621.	1.1	45
203	Intraocular Pharmacokinetics of a Crystalline Lipid Prodrug, Octadecyloxyethyl-Cyclic-Cidofovir, for Cytomegalovirus Retinitis. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2011, 27, 157-162.	0.6	7
204	Persistent Suppression of Ocular Neovascularization with Intravitreal Administration of AAVrh.10 Coding for Bevacizumab. <i>Human Gene Therapy</i> , 2011, 22, 1525-1535.	1.4	24
205	SAFETY AND EFFICACY OF A FLEXIBLE DOSING REGIMEN OF RANIBIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Evidence-Based Ophthalmology</i> , 2011, 12, 188-189.	0.0	0
206	Outcomes following three-line vision loss during treatment of neovascular age-related macular degeneration: subgroup analyses from MARINA and ANCHOR. <i>British Journal of Ophthalmology</i> , 2011, 95, 1713-1718.	2.1	14
207	Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review. <i>British Journal of Ophthalmology</i> , 2011, 95, 308-317.	2.1	66
208	Simple Estimation of Clinically Relevant Lesion Volumes Using Spectral Domain Optical Coherence Tomography in Neovascular Age-Related Macular Degeneration. , 2011, 52, 7792.		11
209	Radiation Treatment for Age-Related Macular Degeneration. <i>Seminars in Ophthalmology</i> , 2011, 26, 121-130.	0.8	19
210	Stereotactic low-voltage x-ray irradiation for age-related macular degeneration. <i>British Journal of Ophthalmology</i> , 2011, 95, 185-188.	2.1	36
211	Validation of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) in Age-Related Macular Degeneration. , 2011, 52, 3354.		79
212	Ranibizumab Treatment for Choroidal Neovascularization from Causes Other than Age-Related Macular Degeneration and Pathological Myopia. <i>Ophthalmologica</i> , 2011, 225, 81-88.	1.0	35
213	Systemic Adverse Drug Reactions Secondary to Anti-VEGF Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration. <i>Current Vascular Pharmacology</i> , 2011, 9, 629-646.	0.8	39
214	Subjective and functional deterioration in recurrences of neovascular AMD are often preceded by morphologic changes in optic coherence tomography. <i>British Journal of Ophthalmology</i> , 2011, 95, 1424-1426.	2.1	24
215	Variants in the <i>APOE</i> Gene Are Associated with Improved Outcome after Anti-VEGF Treatment for Neovascular AMD. , 2011, 52, 4072.		52
216	Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion: 1-year follow-up. <i>British Journal of Ophthalmology</i> , 2011, 95, 56-68.	2.1	26
217	Comparison of Long-Acting Bevacizumab Formulations in the Treatment of Choroidal Neovascularization in a Rat Model. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2011, 27, 219-224.	0.6	57
218	Administration of Repeat Intravitreal Anti-VEGF Drugs by Retina Specialists in an Injection-only Clinic for Patients with Exudative AMD: Patient Acceptance and Safety. <i>Seminars in Ophthalmology</i> , 2011, 26, 380-386.	0.8	15

#	ARTICLE	IF	CITATIONS
219	Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration. <i>Indian Journal of Ophthalmology</i> , 2011, 59, 191.	0.5	59
220	Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. <i>British Journal of Ophthalmology</i> , 2012, 96, 688-693.	2.1	67
221	The past, present, and future of exudative age-related macular degeneration treatment. <i>Middle East African Journal of Ophthalmology</i> , 2012, 19, 43.	0.5	15
222	Antiangiogenic Therapy for Ischemic Retinopathies. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a006411-a006411.	2.9	63
223	Combination therapy with low-dose transpupillary thermotherapy and intravitreal ranibizumab for neovascular age-related macular degeneration: a 24-month prospective randomised clinical study. <i>British Journal of Ophthalmology</i> , 2012, 96, 714-718.	2.1	17
225	Preferred therapies for neovascular age-related macular degeneration. <i>Current Opinion in Ophthalmology</i> , 2012, 23, 182-188.	1.3	43
226	An Update on Intravitreal Injections for Macular Diseases. <i>Asia-Pacific Journal of Ophthalmology</i> , 2012, 1, 43-50.	1.3	0
227	The Predictive Value of OCT Characteristics for the Visual Outcome in Neovascular AMD. <i>Klinische Monatsblätter Für Augenheilkunde</i> , 2012, 229, 343-347.	0.3	9
228	Optical coherence tomography changes before the development of choroidal neovascularization in second eyes of patients with bilateral wet macular degeneration. <i>Eye</i> , 2012, 26, 394-399.	1.1	29
229	Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug. <i>British Journal of Ophthalmology</i> , 2012, 96, 1157-1158.	2.1	117
230	Ranibizumab for age-related macular degeneration. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 371-381.	1.4	39
231	Management of retinal vascular diseases: a patient-centric approach. <i>Eye</i> , 2012, 26, S1-S16.	1.1	74
232	Consensus on the diagnosis, treatment and follow-up of patients with age-related macular degeneration eligible for ranibizumab. <i>Expert Review of Ophthalmology</i> , 2012, 7, 219-225.	0.3	7
233	Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. <i>British Journal of Ophthalmology</i> , 2012, 96, 14-20.	2.1	159
234	Intravitreal Ranibizumab versus Thermal Laser Photocoagulation in the Treatment of Extrafoveal Classic Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. <i>Ophthalmologica</i> , 2012, 228, 93-101.	1.0	12
235	Retinal Venular Caliber Predicts Visual Outcome after Intravitreal Ranibizumab Injection Treatments for Neovascular AMD. , 2012, 53, 37.		13
236	Behavior of SD-OCTâ€œDetected Hyperreflective Foci in the Retina of Anti-VEGFâ€œTreated Patients with Diabetic Macular Edema. , 2012, 53, 5814.		124
237	A framework for modeling ocular drug transport and flow through the eye using micro-CT. <i>Physics in Medicine and Biology</i> , 2012, 57, 6295-6307.	1.6	2

#	ARTICLE	IF	CITATIONS
238	INHIBITORY ACTIVITY OF RANIBIZUMAB, SORAFENIB, AND PAZOPANIB ON LIGHT-INDUCED OVEREXPRESSION OF PLATELET-DERIVED GROWTH FACTOR AND VASCULAR ENDOTHELIAL GROWTH FACTOR A AND THE VASCULAR ENDOTHELIAL GROWTH FACTOR A RECEPTORS 1 AND 2 AND NEUROPIILIN 1 AND 2. <i>Retina</i> , 2012, 32, 1652-1663.	1.0	20
239	Anti-Vascular Endothelial Growth Factor (VEGF) Treatment of Age- Related Macular Degeneration. <i>Current Drug Therapy</i> , 2012, 7, 90-95.	0.2	0
240	TIME TO FIRST TREATMENT. <i>Retina</i> , 2012, 32, 1260-1264.	1.0	54
241	CEREBROVASCULAR ACCIDENTS IN PATIENTS TREATED FOR CHOROIDDAL NEOVASCULARIZATION WITH RANIBIZUMAB IN RANDOMIZED CONTROLLED TRIALS. <i>Retina</i> , 2012, 32, 1821-1828.	1.0	87
242	MORPHOLOGIC CHARACTERISTICS OF IDIOPATHIC JUXTAFOVEAL TELANGIECTASIA USING SPECTRAL-DOMAIN AND POLARIZATION-SENSITIVE OPTICAL COHERENCE TOMOGRAPHY. <i>Retina</i> , 2012, 32, 256-264.	1.0	8
243	TOPICAL BROMFENAC AS AN ADJUNCTIVE TREATMENT WITH INTRAVITREAL RANIBIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2012, 32, 1804-1810.	1.0	39
244	Effectiveness at 1 Year of Monthly versus Variable-Dosing Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-related Macular Degeneration. <i>Retina</i> , 2012, 32, 293-298.	1.0	13
245	CAUSES OF UNSUCCESSFUL RANIBIZUMAB TREATMENT IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION IN CLINICAL SETTINGS. <i>Retina</i> , 2012, 32, 1480-1485.	1.0	44
246	Interventions for age-related visual problems in patients with stroke. <i>The Cochrane Library</i> , 2012, , CD008390.	1.5	13
248	Response to Replacing ranibizumab with bevacizumab on the Pharmaceutical Benefits Scheme: where does the current evidence leave us?. <i>Australasian journal of optometry</i> , The, 2012, 95, 541-543.	0.6	1
249	Diabetic angiopathy and angiogenic defects. <i>Fibrogenesis and Tissue Repair</i> , 2012, 5, 13.	3.4	43
250	Preclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primates. <i>Gene Therapy</i> , 2012, 19, 999-1009.	2.3	46
251	Neovascular Age-Related Macular Degeneration. <i>Ophthalmologica</i> , 2012, 227, 11-20.	1.0	58
252	FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2012, 250, 1737-1744.	1.0	22
253	Aflibercept: a Potent Vascular Endothelial Growth Factor Antagonist for Neovascular Age-Related Macular Degeneration and Other Retinal Vascular Diseases. <i>Biologics in Therapy</i> , 2012, 2, 3.	1.8	17
254	Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degeneration: A retrospective study of 58 patients. <i>Journal Francais D'Ophtalmologie</i> , 2012, 35, 661-666.	0.2	11
255	Vascular Endothelial Growth Factor in Patients with Exudative Age-related Macular Degeneration Treated with Ranibizumab. <i>Ophthalmology</i> , 2012, 119, 2082-2086.	2.5	61
256	Comparison of outcomes after switching treatment from intravitreal bevacizumab to ranibizumab in neovascular age-related macular degeneration. <i>Canadian Journal of Ophthalmology</i> , 2012, 47, 159-164.	0.4	25

#	ARTICLE	IF	CITATIONS
257	Canadian expert consensus: optimal treatment of neovascular age-related macular degeneration. Canadian Journal of Ophthalmology, 2012, 47, 227-235.	0.4	22
259	Evaluation of Changes in Choroidal Neovascularization Secondary to Age-related Macular Degeneration after Anti-VEGF Therapy Using Spectral Domain Optical Coherence Tomography. Current Eye Research, 2012, 37, 438-445.	0.7	19
260	Extended Release of Bevacizumab by Thermosensitive Biodegradable and Biocompatible Hydrogel. Biomacromolecules, 2012, 13, 40-48.	2.6	109
261	Vascular endothelial growth factors in retinal and choroidal neovascular diseases. Annals of Medicine, 2012, 44, 1-17.	1.5	46
263	Macular Epiretinal Brachytherapy in Treated Age-related Macular Degeneration. Ophthalmology, 2012, 119, 1425-1431.	2.5	37
264	Role of Vascular Endothelial Growth Factor Polymorphisms in the Treatment Success in Patients with Wet Age-related Macular Degeneration. Ophthalmology, 2012, 119, 1615-1620.	2.5	32
265	Verteporfin plus Ranibizumab for Choroidal Neovascularization in Age-related Macular Degeneration. Ophthalmology, 2012, 119, 992-1000.	2.5	119
266	Verteporfin plus Ranibizumab for Choroidal Neovascularization in Age-Related Macular Degeneration. Ophthalmology, 2012, 119, 1001-1010.	2.5	115
267	Subfoveal Choroidal Thickness after Ranibizumab Therapy for Neovascular Age-related Macular Degeneration: 12-Month Results. Ophthalmology, 2012, 119, 1621-1627.	2.5	152
268	Fixed-Interval Versus OCT-Guided Variable Dosing of Intravitreal Bevacizumab in the Management of Neovascular Age-Related Macular Degeneration: A 12-Month Randomized Prospective Study. American Journal of Ophthalmology, 2012, 153, 481-489.e1.	1.7	22
269	Outcomes of cataract surgery in patients with neovascular age-related macular degeneration in the era of anti-vascular endothelial growth factor therapy. Journal of Cataract and Refractive Surgery, 2012, 38, 677-682.	0.7	34
270	Aflibercept in wet age-related macular degeneration: a perspective review. Therapeutic Advances in Chronic Disease, 2012, 3, 153-161.	1.1	39
271	Long-term visual acuity in patients with age-related macular degeneration and persistence of subretinal fluid after treatment with ranibizumab. Archivos De La Sociedad Espanola De Oftalmologia, 2012, 87, 237-246.	0.1	1
272	Drugs used in ocular treatment. Side Effects of Drugs Annual, 2012, 34, 761-768.	0.6	0
273	Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration. Ophthalmology, 2012, 119, 2537-2548.	2.5	1,947
274	Impact of Loading Phase, Initial Response and CFH Genotype on the Long-Term Outcome of Treatment for Neovascular Age-Related Macular Degeneration. PLoS ONE, 2012, 7, e42014.	1.1	34
275	A Safety Review and Meta-Analyses of Bevacizumab and Ranibizumab: Off-Label versus Goldstandard. PLoS ONE, 2012, 7, e42701.	1.1	119
276	New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration. Journal of Ophthalmology, 2012, 2012, 1-7.	0.6	15

#	ARTICLE	IF	CITATIONS
277	Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular Degeneration. <i>Journal of Ophthalmology</i> , 2012, 2012, 1-8.	0.6	11
278	Antivascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration. <i>Journal of Ophthalmology</i> , 2012, 2012, 1-12.	0.6	39
279	Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability. <i>Journal of Ophthalmology</i> , 2012, 2012, 1-11.	0.6	43
280	Treatment of Neovascular Age Related Macular Degeneration. , 2012, , .		0
281	Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting. <i>Clinical Ophthalmology</i> , 2012, 6, 1149.	0.9	21
282	Anti-Angiogenic Treatment for Exudative Age-Related Macular Degeneration: New Strategies are Underway. <i>Current Angiogenesis</i> , 2012, 1, 318-334.	0.1	5
283	A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration. <i>Clinical Ophthalmology</i> , 2012, 6, 1519.	0.9	13
284	Promising Treatment Strategies for Neovascular AMD: Anti-VEGF Therapy. , 0, , .		0
285	Exogenous group G Streptococcus endophthalmitis following intravitreal ranibizumab injection. <i>Clinical Ophthalmology</i> , 2012, 6, 1399.	0.9	3
286	Profile of ranibizumab: efficacy and safety for the treatment of wet age-related macular degeneration. <i>Therapeutics and Clinical Risk Management</i> , 2012, 8, 343.	0.9	15
287	Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 585-591.	0.9	53
288	Anatomic response of occult choroidal neovascularization to intravitreal ranibizumab: a study by indocyanine green angiography. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2012, 250, 479-484.	1.0	17
289	Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. <i>Angiogenesis</i> , 2012, 15, 171-185.	3.7	838
290	Cost-Effectiveness Analysis of Ranibizumab versus Verteporfin Photodynamic Therapy, Pegaptanib Sodium, and Best Supportive Care for the Treatment of Age-Related Macular Degeneration in Greece. <i>Clinical Therapeutics</i> , 2012, 34, 446-456.	1.1	21
291	Interobserver variability for retreatment indications after Ranibizumab loading doses in neovascular age-related macular degeneration. <i>Acta Ophthalmologica</i> , 2012, 90, 49-55.	0.6	10
292	Ranibizumab therapy for choroidal neovascularization secondary to non-â€œage-related macular degeneration causes. <i>Clinical and Experimental Ophthalmology</i> , 2012, 40, 67-72.	1.3	17
293	Three-year results of visual outcome with disease activity-guided ranibizumab algorithm for the treatment of exudative age-related macular degeneration. <i>Acta Ophthalmologica</i> , 2013, 91, 526-530.	0.6	24
294	Ranibizumab for exudative AMD in a clinical setting: differences between 2007 and 2010. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2013, 251, 2499-2503.	1.0	20

#	ARTICLE	IF	CITATIONS
295	Optimising assessment intervals improves visual outcomes in ranibizumab-treated age-related neovascular degeneration: using the stability phase as a benchmark. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2013, 251, 2327-2330.	1.0	3
296	In-vivo investigation of laser-induced choroidal neovascularization in rat using spectral-domain optical coherence tomography (SD-OCT). <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2013, 251, 1293-1301.	1.0	15
297	Prospective study evaluating the predictability of need for retreatment with intravitreal ranibizumab for age-related macular degeneration. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2013, 251, 697-704.	1.0	51
298	Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2013, 251, 453-458.	1.0	74
299	Drug-induced uveitis. <i>Journal of Ophthalmic Inflammation and Infection</i> , 2013, 3, 43.	1.2	64
300	Ranibizumab: A Review of Its Use in the Treatment of Neovascular Age-Related Macular Degeneration. <i>Drugs and Aging</i> , 2013, 30, 331-358.	1.3	42
301	Aflibercept for the Treatment of Age-Related Macular Degeneration. <i>Ophthalmology and Therapy</i> , 2013, 2, 89-98.	1.0	26
302	Treatment Paradigms in Neovascular AMD. <i>Current Ophthalmology Reports</i> , 2013, 1, 12-19.	0.5	0
303	Decisional answer tree analysis of exudative age-related macular degeneration treatment outcomes. <i>International Ophthalmology</i> , 2013, 33, 467-474.	0.6	2
304	Current Anti-vascular Endothelial Growth Factor Dosing Regimens. <i>Ophthalmology</i> , 2013, 120, S3-S7.	2.5	86
305	16 and 24 Gy Low-voltage X-ray Irradiation With Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration: 12-Month Outcomes. <i>American Journal of Ophthalmology</i> , 2013, 155, 1000-1008.e2.	1.7	7
306	Different anti-vascular endothelial growth factor treatments and regimens and their outcomes in neovascular age-related macular degeneration: a literature review. <i>British Journal of Ophthalmology</i> , 2013, 97, 1497-1507.	2.1	43
307	Single-session photodynamic therapy combined with intravitreal ranibizumab for neovascular age-related macular degeneration: a comprehensive functional retinal assessment. <i>Documenta Ophthalmologica</i> , 2013, 127, 217-225.	1.0	7
309	The Impact of Short-Term Topical Gatifloxacin and Moxifloxacin on Bacterial Injection After Hypodermic Needle Passage Through Human Conjunctiva. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2013, 29, 450-455.	0.6	1
310	Vascular endothelial growth factor and its inhibitor in age-related macular degeneration. <i>Taiwan Journal of Ophthalmology</i> , 2013, 3, 128-133.	0.3	3
312	Introduction: Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2013, 120, S1-S2.	2.5	4
313	Fixation stability measurements in patients with neovascular age-related macular degeneration treated with ranibizumab. <i>Canadian Journal of Ophthalmology</i> , 2013, 48, 394-399.	0.4	22
315	Switching Anti-vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration. <i>American Journal of Ophthalmology</i> , 2013, 156, 1-2.e1.	1.7	38

#	ARTICLE	IF	CITATIONS
317	Fixation stability as a goal in the treatment of macular disease. Canadian Journal of Ophthalmology, 2013, 48, 364-367.	0.4	20
318	Retreatment by series of three intravitreal injections of ranibizumab in neovascular age-related macular degeneration: long-term outcomes. Graefe's Archive for Clinical and Experimental Ophthalmology, 2013, 251, 1901-1907.	1.0	2
319	Aflibercept: Newly Approved for the Treatment of Macular Edema Following Central Retinal Vein Occlusion. Annals of Pharmacotherapy, 2013, 47, 819-827.	0.9	14
320	The SECURE Study. Ophthalmology, 2013, 120, 130-139.	2.5	81
321	Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration. Ophthalmology, 2013, 120, 1046-1056.	2.5	432
322	Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of injections every 4 weeks, 6 weeks and 8 weeks. Acta Ophthalmologica, 2013, 91, e456-e461.	0.6	23
323	Pharmacotherapy of Age-Related Macular Degeneration. , 2013, , 1213-1255.		5
324	Recent Advances in the Management of Neovascular Glaucoma. Seminars in Ophthalmology, 2013, 28, 165-172.	0.8	43
325	Anti-VEGF Therapy for AMD: Results and Guidelines. , 2013, , 233-245.		1
326	Ranibizumab: points to consider when using it to treat neovascular age-related macular degeneration according to EU labelling. Drugs and Therapy Perspectives, 2013, 29, 268-274.	0.3	0
327	Aflibercept ophthalmic solution: drug development and clinical uses. Clinical Investigation, 2013, 3, 1045-1056.	0.0	2
329	Influence of seasonal sunlight intensity and iris color on the anti-VEGF therapy for neovascular age-related macular degeneration. Eye, 2013, 27, 1169-1173.	1.1	5
330	Anti-vascular endothelial growth factor in age-related macular degeneration: Puzzle or a silent beginning!. Indian Journal of Ophthalmology, 2013, 61, 475.	0.5	3
331	Progression of Lesion Size in Untreated Eyes With Exudative Age-Related Macular Degeneration. JAMA Ophthalmology, 2013, 131, 335.	1.4	31
332	Vitreous Inflammation Associated with Intravitreal Anti-VEGF Pharmacotherapy. Mediators of Inflammation, 2013, 2013, 1-6.	1.4	57
333	Combination therapy for the treatment of neovascular age-related macular degeneration. Current Opinion in Ophthalmology, 2013, 24, 233-238.	1.3	13
334	A 12-MONTH PROSPECTIVE TRIAL OF INJECT AND EXTEND REGIMEN FOR RANIBIZUMAB TREATMENT OF AGE-RELATED MACULAR DEGENERATION. Retina, 2013, 33, 1351-1358.	1.0	62
335	Systemic effects of intravitreal vascular endothelial growth factor inhibitors. Current Opinion in Ophthalmology, 2013, 24, 197-204.	1.3	12

#	ARTICLE	IF	CITATIONS
336	An epidemiological study of neovascular age-related macular degeneration in Germany. <i>Current Medical Research and Opinion</i> , 2013, 29, 1391-1397.	0.9	10
337	Treatment of Exudative Age-Related Macular Degeneration with Intravitreal Ranibizumab in Clinical Practice: A 3-Year Follow-Up. <i>Ophthalmologica</i> , 2013, 229, 158-167.	1.0	11
338	Current Choroidal Neovascularization Treatment. <i>Ophthalmologica</i> , 2013, 230, 55-61.	1.0	21
339	Incidence and Risk Factors for Macular Hemorrhage Following Intravitreal Ranibizumab Injection for Neovascular Age-Related Macular Degeneration. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2013, 29, 556-559.	0.6	13
340	Eye disease in older people. <i>Reviews in Clinical Gerontology</i> , 2013, 23, 234-250.	0.5	2
341	Comparison of Ranibizumab monotherapy versus combination of Ranibizumab with photodynamic therapy with neovascular age-related macular degeneration. <i>Acta Ophthalmologica</i> , 2013, 91, e178-83.	0.6	25
342	Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - A noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. <i>Acta Ophthalmologica</i> , 2013, 91, 540-546.	0.6	134
343	Long-Term Intraocular Pressure Changes in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab. <i>Ophthalmologica</i> , 2013, 229, 168-172.	1.0	26
344	Lessons learnt inform our approach to new anti-vascular endothelial growth factor treatments for neovascular age-related macular degeneration. <i>Clinical and Experimental Ophthalmology</i> , 2013, 41, 723-726.	1.3	2
345	Intravitreal injections at the Massachusetts Eye and Ear Infirmary: analysis of treatment indications and postinjection endophthalmitis rates. <i>British Journal of Ophthalmology</i> , 2013, 97, 460-465.	2.1	55
347	Cataract Conversion Assessment using Lens Opacity Classification System III and Wisconsin Cataract Grading System. , 2013, 54, 280.		21
348	Improving treatment provision of Wet AMD with intravitreal ranibizumab. <i>BMJ Quality Improvement Reports</i> , 2013, 2, u201733.w993.	0.8	2
349	Information Used to Decide on Retreatment of Exudative Age-Related Macular Degeneration with anti-VEGF in Clinical Practice. <i>European Journal of Ophthalmology</i> , 2013, 23, 108-113.	0.7	4
350	ANATOMICAL MEASURES AS PREDICTORS OF VISUAL OUTCOMES IN RANIBIZUMAB-TREATED EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2013, 33, 23-34.	1.0	64
351	MYOCARDIAL INFARCTION AFTER INTRAVITREAL VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS. <i>Retina</i> , 2013, 33, 920-927.	1.0	42
352	Long-term results of intravitreal ranibizumab treatment for neovascular age-related macular degeneration in clinical practice. <i>Expert Review of Ophthalmology</i> , 2013, 8, 37-40.	0.3	1
353	EXPRESSION OF SIRT1 IN CHOROIDAL NEOVASCULAR MEMBRANES. <i>Retina</i> , 2013, 33, 862-866.	1.0	18
354	CORRELATION OF FOVEAL MICROSTRUCTURAL CHANGES WITH VISION AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2013, 33, 964-970.	1.0	12

#	ARTICLE	IF	CITATIONS
355	The Results of Switching between 2 Anti-VEGF Drugs, Bevacizumab and Ranibizumab, in the Treatment of Neovascular Age-related Macular Degeneration. <i>European Journal of Ophthalmology</i> , 2013, 23, 553-557.	0.7	23
356	Bevacizumab Monotherapy Versus Combined Therapy with Photodynamic Therapy for Occult Choroidal Neovascularization in Age-Related Macular Degeneration. <i>Journal of Korean Ophthalmological Society</i> , 2013, 54, 1554.	0.0	0
357	Critical appraisal of ranibizumab in the treatment of diabetic macular edema. <i>Clinical Ophthalmology</i> , 2013, 7, 1257.	0.9	19
358	Three-year follow-up of visual outcome and quality of life in patients with age-related macular degeneration. <i>Clinical Ophthalmology</i> , 2013, 7, 395.	0.9	10
359	Two-year outcomes of pro re nata ranibizumab monotherapy for exudative age-related macular degeneration in Japanese patients. <i>Clinical Ophthalmology</i> , 2013, 7, 757.	0.9	5
360	Clinical trials in Brazilian journals of ophthalmology: where we are. <i>Arquivos Brasileiros De Oftalmologia</i> , 2013, 76, 21-25.	0.2	0
361	Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema. <i>Clinical Interventions in Aging</i> , 2013, 8, 467.	1.3	34
362	Aflibercept in wet AMD: specific role and optimal use. <i>Drug Design, Development and Therapy</i> , 2013, 7, 711.	2.0	108
363	Study In Vivo Intraocular Biocompatibility of In Situ Gelation Hydrogels: Poly(2-Ethyl) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 427 Td (Oxaz Pluronic F127. <i>PLoS ONE</i> , 2013, 8, e67495.	1.1	27
364	Anti VEGF Agents for Age Related Macular Degeneration. , 2013, , .		0
365	Implantable MicroPump for Drug Delivery in Patients with Diabetic Macular Edema. <i>Translational Vision Science and Technology</i> , 2014, 3, 5.	1.1	57
366	Controlled release bevacizumab in thermoresponsive hydrogel found to inhibit angiogenesis. <i>Bio-Medical Materials and Engineering</i> , 2014, 24, 1941-1950.	0.4	19
367	Intravitreal Anti-VEGF Therapy for Vascularized Pigment Epithelium Detachment in Age-Related Macular Degeneration. <i>European Journal of Ophthalmology</i> , 2014, 24, 402-408.	0.7	4
368	Serum Concentration of Vascular Endothelial Growth Factor after Bilateral Intravitreal Injection of Bevacizumab. <i>Korean Journal of Ophthalmology: KJO</i> , 2014, 28, 32.	0.5	12
369	Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema. <i>Clinical Ophthalmology</i> , 2014, 8, 1611.	0.9	100
370	Biocompatible Reverse Thermal Gel Sustains the Release of Intravitreal Bevacizumab In Vivo. , 2014, 55, 469.		77
371	Ranibizumab for the treatment of degenerative ocular conditions. <i>Clinical Ophthalmology</i> , 2014, 8, 1187.	0.9	17
372	Epimacular brachytherapy for wet AMD: current perspectives. <i>Clinical Ophthalmology</i> , 2014, 8, 1661.	0.9	7

#	ARTICLE	IF	CITATIONS
373	Intravitreal anti-vascular endothelial growth factor treatment for retinal diseases. Journal of the Korean Medical Association, 2014, 57, 614.	0.1	0
374	Ranibizumab, Verteporfin Photodynamic Therapy or Observation for the Treatment of Myopic Choroidal Neovascularization: Cost Effectiveness in the UK. Drugs and Aging, 2014, 31, 837-848.	1.3	13
375	25th RCOphth Congress, President's Session paper: 25 years of progress in medical retina. Eye, 2014, 28, 1041-1052.	1.1	4
376	Comparative study of photodynamic therapy monotherapy versus triplemanagement in age-related macular degeneration. Turkish Journal of Medical Sciences, 2014, 44, 889-895.	0.4	4
377	Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen. British Journal of Ophthalmology, 2014, 98, 1192-1196.	2.1	61
378	Ranibizumab Treatment in Age-Related Macular Degeneration: A Meta-Analysis of One-Year Results. Klinische Monatsblätter Fur Augenheilkunde, 2014, 231, 427-431.	0.3	9
379	Trends in Age-Related Macular Degeneration Management in Singapore. Optometry and Vision Science, 2014, 91, 872-877.	0.6	13
380	ANTI-VEGF TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2014, 34, 1531-1538.	3.0	115
381	ENDOPHTHALMITIS ASSOCIATED WITH INTRAVITREAL INJECTIONS. Retina, 2014, 34, 18-23.	1.0	74
382	EXTEND II: An Open-Label Phase III Multicentre Study to Evaluate Efficacy and Safety of Ranibizumab in Chinese Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. BioDrugs, 2014, 28, 527-536.	2.2	10
383	Cardiovascular Events and Bleeding Risk Associated With Intravitreal Antivascular Endothelial Growth Factor Monoclonal Antibodies. JAMA Ophthalmology, 2014, 132, 1317.	1.4	108
384	Bimonthly Ranibizumab for Neovascular Age-Related Macular Degeneration. Ophthalmologica, 2014, 231, 80-85.	1.0	9
385	RESULTS OF INTRAVITREAL RANIBIZUMAB WITH A PRN REGIMEN IN THE TREATMENT OF EXTRAFOVEAL AND JUXTAFOVEAL NEOVASCULAR MEMBRANES IN AGE-RELATED MACULAR DEGENERATION. Retina, 2014, 34, 860-867.	1.0	8
386	Electrophysiological toxicity testing of <sc>VEGF</sc> Trap&EYE in an isolated perfused vertebrate retina organ culture model. Acta Ophthalmologica, 2014, 92, e305-11.	0.6	13
387	Effects of core vitrectomy in the treatment of age-related macular degeneration. Acta Ophthalmologica, 2014, 92, 465-472.	0.6	9
388	Topical Ranibizumab inhibits inflammatory corneal hem&Eand lymphangiogenesis. Acta Ophthalmologica, 2014, 92, 143-148.	0.6	33
389	Intraocular pressure changes after repeated intravitreal antivascular endothelial growth factor injections in patients with neovascular age-related macular degeneration with or without glaucoma. Taiwan Journal of Ophthalmology, 2014, 4, 28-32.	0.3	0
390	Clinical Utilization of Anti-VEGF Agents and Disease Monitoring in Neovascular Age-Related Macular Degeneration. American Journal of Ophthalmology, 2014, 157, 825-833.e1.	1.7	77

#	ARTICLE	IF	CITATIONS
391	Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2014, 252, 647-655.	1.0	69
392	Aqueous vascular endothelial growth factor and ranibizumab concentrations after monthly and bimonthly intravitreal injections of ranibizumab for age-related macular degeneration. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2014, 252, 1033-1039.	1.0	13
393	Efficacy and safety of widely used treatments for macular oedema secondary to retinal vein occlusion: a systematic review. <i>BMC Ophthalmology</i> , 2014, 14, 7.	0.6	46
394	Tunable sustained intravitreal drug delivery system for daunorubicin using oxidized porous silicon. <i>Journal of Controlled Release</i> , 2014, 178, 46-54.	4.8	55
395	Current and investigational pharmacotherapeutic approaches for modulating retinal angiogenesis. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 375-391.	1.3	21
396	Systemic Vascular Safety of Ranibizumab for Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2014, 121, 2193-2203.e7.	2.5	64
397	Twenty-four-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2014, 121, 2181-2192.	2.5	377
398	A safety evaluation of ranibizumab in the treatment of age-related macular degeneration. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 1259-1270.	1.0	13
399	Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. <i>The Cochrane Library</i> , 2014, , CD005139.	1.5	255
400	Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD. <i>Wiener Klinische Wochenschrift</i> , 2014, 126, 355-359.	1.0	7
402	Bimonthly injections of ranibizumab for age-related macular degeneration. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2014, 252, 1545-1551.	1.0	10
403	Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). <i>British Journal of Ophthalmology</i> , 2014, 98, 1144-1167.	2.1	463
405	Safety Monitoring of Ophthalmic Biologics: A Systematic Review of Pre- and Postmarketing Safety Data. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2014, 30, 729-751.	0.6	19
406	Visual Acuity after Cataract Surgery in Patients with Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2014, 121, 1229-1236.	2.5	41
407	The Neovascular Age-Related Macular Degeneration Database: Multicenter Study of 976 Ranibizumab Injections. <i>Ophthalmology</i> , 2014, 121, 1092-1101.	2.5	317
408	Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration. <i>Ophthalmology</i> , 2014, 121, 193-201.	2.5	693
409	Morphologic Parameters Relevant for Visual Outcome During Anti-Angiogenic Therapy of Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2014, 121, 1237-1245.	2.5	146
410	Management of Thick Submacular Hemorrhage With Subretinal Tissue Plasminogen Activator and Pneumatic Displacement for Age-Related Macular Degeneration. <i>American Journal of Ophthalmology</i> , 2014, 157, 1250-1257.	1.7	91

#	ARTICLE	IF	CITATIONS
411	Antivascular endothelial growth factor therapies for neovascular age-related macular degeneration: Search for the optimized treatment regimen. Taiwan Journal of Ophthalmology, 2014, 4, 3-8.	0.3	4
412	Functional and anatomical outcome of eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab following an exit strategy regimen. British Journal of Ophthalmology, 2014, 98, 1197-1200.	2.1	15
413	Retention of good visual acuity in eyes with neovascular age-related macular degeneration and chronic refractory subfoveal subretinal fluid. Saudi Journal of Ophthalmology, 2014, 28, 129-133.	0.3	24
414	Anti-VEGF Treatment Patterns for Neovascular Age-Related Macular Degeneration Among Medicare Beneficiaries. American Journal of Ophthalmology, 2014, 158, 537-543.e2.	1.7	55
415	Effect of Switching Therapy to Pegaptanib in Eyes With the Persistent Cases of Exudative Age-Related Macular Degeneration. Medicine (United States), 2014, 93, e116.	0.4	10
416	Stereotactic low voltage x-ray radiotherapy for treating neovascular age-related macular degeneration. Expert Review of Ophthalmology, 2014, 9, 153-158.	0.3	0
417	Therapeutic Monoclonal Antibodies and Fragments: Ranibizumab. Developments in Ophthalmology, 2016, 55, 246-251.	0.1	7
418	Effect of charred Radix et Rhizoma Rhei in a laser-induced choroidal neovascularization murine model. Molecular Medicine Reports, 2015, 11, 2896-2902.	1.1	3
419	Intravitreal treatment in patients with exudative age-related macular degeneration and visual acuity ≤ 0.05 . BMC Ophthalmology, 2015, 15, 138.	0.6	1
420	Finding the Optimal Treatment Plan for Exudative AMD. International Ophthalmology Clinics, 2015, 55, 103-112.	0.3	4
421	REFRACTORY INTRARETINAL OR SUBRETINAL FLUID IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIZUBIMAB. Retina, 2015, 35, 1195-1201.	1.0	58
422	RELATIONSHIP BETWEEN VISUAL PROGNOSIS AND DELAY OF INTRAVITREAL INJECTION OF RANIBIZUMAB WHEN TREATING AGE-RELATED MACULAR DEGENERATION. Retina, 2015, 35, 1331-1338.	1.0	20
423	Current state of therapeutic strategies with ranibizumab in neovascular age-related macular degeneration. Current Opinion in Ophthalmology, 2015, 26, 200-205.	1.3	0
424	Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey. Clinical Ophthalmology, 2015, 9, 2243.	0.9	56
425	Optimizing the Anti-VEGF Treatment Strategy for Neovascular Age-Related Macular Degeneration: From Clinical Trials to Real-Life Requirements. Translational Vision Science and Technology, 2015, 4, 6.	1.1	44
426	Occurrence of Macular Hematoma after Ranibizumab Treatment for Age-Related Macular Degeneration. European Journal of Ophthalmology, 2015, 25, 163-167.	0.7	6
427	Individualized Treatment of Neovascular Age-Related Macular Degeneration: What are Patients Gaining? Or Losing?. Journal of Clinical Medicine, 2015, 4, 1079-1101.	1.0	26
428	22 anti-vascular endothelial growth factor (anti-VEGF) therapy Optical Coherence Tomography and Anti-Vascular Endothelial Growth Factor Therapy. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
429	Current perspectives on ranibizumab. <i>Clinical Ophthalmology</i> , 2015, 9, 533.	0.9	15
430	Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in development. <i>Clinical Ophthalmology</i> , 2015, 9, 1001.	0.9	35
431	The Clinical Effectiveness and Cost-Effectiveness of Screening for Age-Related Macular Degeneration in Japan: A Markov Modeling Study. <i>PLoS ONE</i> , 2015, 10, e0133628.	1.1	31
432	Effects of Vitreomacular Traction on Ranibizumab Treatment Response in Eyes with Neovascular Age-related Macular Degeneration. <i>Korean Journal of Ophthalmology: KJO</i> , 2015, 29, 396.	0.5	5
433	Potential role of lampalizumab for treatment of geographic atrophy. <i>Clinical Ophthalmology</i> , 2015, 9, 1049.	0.9	20
434	Long-Term Visual Outcome in Wet Age-Related Macular Degeneration Patients Depending on the Number of Ranibizumab Injections. <i>Journal of Ophthalmology</i> , 2015, 2015, 1-5.	0.6	8
435	Long-Term Outcomes in Eyes Receiving Fixed-Interval Dosing of Anti-“Vascular Endothelial Growth Factor Agents for Wet Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2015, 122, 803-808.	2.5	112
436	Time to Initial Clinician-Reported Inactivation of Neovascular Age-Related Macular Degeneration Treated Primarily withÂRanibizumab. <i>Ophthalmology</i> , 2015, 122, 589-594.e1.	2.5	25
437	Prevalence and incidence of blindness and other degrees of sight impairment in patients treated for neovascular age-related macular degeneration in a well-defined region of the United Kingdom. <i>Eye</i> , 2015, 29, 403-408.	1.1	19
438	Parafoveal contributions to retinal function during ranibizumab therapy for age-related macular degeneration. <i>Canadian Journal of Ophthalmology</i> , 2015, 50, 37-43.	0.4	1
439	From Pathobiology to the Targeting of Pericytes for the Treatment of Diabetic Retinopathy. <i>Current Diabetes Reports</i> , 2015, 15, 573.	1.7	42
440	Pigment Epithelial Detachment Followed byÂRetinal Cystoid Degeneration Leads toÂVision Loss in Treatment of Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2015, 122, 822-832.	2.5	170
441	Genetic predictive biomarkers of anti-VEGF treatment response in patients with neovascular age-related macular degeneration. <i>Survey of Ophthalmology</i> , 2015, 60, 138-152.	1.7	31
442	Comparative Safety and Tolerability of Anti-VEGF Therapy in Age-Related Macular Degeneration. <i>Drug Safety</i> , 2015, 38, 279-293.	1.4	20
443	Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results. <i>Eye</i> , 2015, 29, 342-349.	1.1	35
444	Routine versus As-Needed Bevacizumab withÂ12-Weekly Assessment Intervals forÂNeovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2015, 122, 1348-1355.	2.5	11
445	Clinical characteristics and anti-vascular endothelial growth factor effect of choroidal neovascularization in younger patients in Taiwan. <i>Taiwan Journal of Ophthalmology</i> , 2015, 5, 76-84.	0.3	5
446	The stereotypical molecular cascade in neovascular age-related macular degeneration: the role of dynamic reciprocity. <i>Eye</i> , 2015, 29, 1416-1426.	1.1	1

#	ARTICLE	IF	CITATIONS
447	Advances in pharmacotherapy for wet age-related macular degeneration. Expert Opinion on Pharmacotherapy, 2015, 16, 1769-1781.	0.9	27
448	Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration. Expert Opinion on Biological Therapy, 2015, 15, 1349-1358.	1.4	20
449	The Effects of Cataract Surgery on Patients With Wet Macular Degeneration. American Journal of Ophthalmology, 2015, 160, 487-492.e1.	1.7	32
452	Defining response to anti-VEGF therapies in neovascular AMD. Eye, 2015, 29, 721-731.	1.1	214
453	Individualized ranibizumab therapy strategies in year 3 after as-needed treatment for polypoidal choroidal vasculopathy. BMC Ophthalmology, 2015, 15, 37.	0.6	7
454	Comparing different dosing regimens of bevacizumab in the treatment of neovascular macular degeneration: study protocol for a randomised controlled trial. Trials, 2015, 16, 85.	0.7	7
455	Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial. Lancet, The, 2015, 386, 2395-2403.	6.3	154
456	Factors Associated with Recurrence of Age-Related Macular Degeneration after Anti-Vascular Endothelial Growth Factor Treatment. Ophthalmology, 2015, 122, 2303-2310.	2.5	92
457	Anti-VEGF therapies in the treatment of choroidal neovascularisation secondary to non-age-related macular degeneration: a systematic review. BMJ Open, 2015, 5, e007746-e007746.	0.8	20
458	Baseline Predictors of 12-Month Treatment Response to Ranibizumab in Patients With Wet Age-Related Macular Degeneration. American Journal of Ophthalmology, 2015, 160, 1014-1023.e2.	1.7	59
459	Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration. Ophthalmology, 2015, 122, 2514-2522.	2.5	226
460	Factors affecting visual acuity after one year of follow up after repeated intravitreal ranibizumab for macular degeneration. Saudi Journal of Ophthalmology, 2015, 29, 187-191.	0.3	3
461	One-Year Outcomes of Aflibercept in Recurrent or Persistent Neovascular Age-Related Macular Degeneration. American Journal of Ophthalmology, 2015, 159, 426-436.e2.	1.7	74
462	Treatment Outcomes After 3 Years in Neovascular Age-Related Macular Degeneration Using a Treat-and-Extend Regimen. American Journal of Ophthalmology, 2015, 159, 3-8.e1.	1.7	108
463	A randomized trial to compare the safety and efficacy of two ranibizumab dosing regimens in a Turkish cohort of patients with choroidal neovascularization secondary to AMD. Acta Ophthalmologica, 2015, 93, e458-64.	0.6	13
464	Triple Subconjunctival Bevacizumab Injection for Early Corneal Recurrent Pterygium: One-Year Follow-Up. Journal of Ocular Pharmacology and Therapeutics, 2015, 31, 106-113.	0.6	18
466	A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK. Clinical Ophthalmology, 2016, 10, 87.	0.9	27
467	Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up. Clinical Ophthalmology, 2016, 10, 1047.	0.9	4

#	ARTICLE	IF	CITATIONS
468	Epidemiological and Clinical Baseline Characteristics as Predictive Biomarkers of Response to Anti-VEGF Treatment in Patients with Neovascular AMD. <i>Journal of Ophthalmology</i> , 2016, 2016, 1-13.	0.6	26
469	Effect of Fluid Status at Week 12 on Visual and Anatomic Outcomes at Week 52 in the VIEW 1 and 2 Trials. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2016, 47, 238-244.	0.4	8
470	BRIDGE ARCH-SHAPED SEROUS RETINAL DETACHMENT IN AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2016, 36, 476-482.	1.0	10
471	INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2016, 36, 859-867.	1.0	48
472	EVALUATION OF A TELEMEDICINE MODEL TO FOLLOW UP PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2016, 36, 279-284.	1.0	20
473	Systemic safety of intravitreal anti-vascular endothelial growth factor agents in age-related macular degeneration. <i>Current Opinion in Ophthalmology</i> , 2016, 27, 224-243.	1.3	14
474	Characteristics and Predictors of Early and Delayed Responders to Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Retrospective Analysis from the ANCHOR, MARINA, HARBOR, and CATT Trials. <i>Ophthalmologica</i> , 2016, 236, 193-200.	1.0	10
475	Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study. <i>British Journal of Ophthalmology</i> , 2016, 100, 1623-1628.	2.1	104
477	Screening for Impaired Visual Acuity in Older Adults. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 915.	3.8	77
478	Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2016, 123, 617-624.	2.5	106
479	Patterns of Early and Delayed Visual Response to Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration. <i>JAMA Ophthalmology</i> , 2016, 134, 545.	1.4	13
480	Guidelines for the Management of Wet Age-Related Macular Degeneration: Recommendations from a Panel of Greek Experts. <i>Advances in Therapy</i> , 2016, 33, 715-726.	1.3	11
481	Anti-vascular Endothelial Growth Factor (VEGF) Treatment in Neovascular Age-Related Macular Degeneration: Outcomes and Outcome Predictors. <i>Essentials in Ophthalmology</i> , 2016, , 31-65.	0.0	0
482	Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an instrumental variable analysis of the AURA study. <i>Eye</i> , 2016, 30, 1063-1071.	1.1	40
484	UK Age-Related Macular Degeneration Electronic Medical Record System (AMD EMR) Users Group Report IV. <i>Ophthalmology</i> , 2016, 123, 2386-2392.	2.5	31
485	The Cost-Effectiveness of Ranibizumab Treat and Extend Regimen Versus Aflibercept in the UK. <i>Advances in Therapy</i> , 2016, 33, 1660-1676.	1.3	14
486	TREATMENT OUTCOMES FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH INITIAL VISION BETTER THAN 20/40 USING A TREAT-AND-EXTEND REGIMEN. <i>Retina</i> , 2016, 36, 875-880.	1.0	10
487	Fluctuation Speed as a New Criterion to Evaluate the Efficiency of Intravitreal Anti-VEGF Drugs. <i>Ophthalmologica</i> , 2016, 235, 242-242.	1.0	1

#	ARTICLE	IF	CITATIONS
488	INTRAVITREAL RANIBIZUMAB THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND THE RISK OF STROKE. <i>Retina</i> , 2016, 36, 2166-2174.	1.0	18
489	Gene Therapy for Age-Related Macular Degeneration. <i>Asia-Pacific Journal of Ophthalmology</i> , 2016, 5, 300-303.	1.3	14
490	RETROSPECTIVE REVIEW OF LUCENTIS â€œTREAT AND EXTENDâ€•PATTERNS AND OUTCOMES IN AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2016, 36, 272-278.	1.0	10
491	Interventions for Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2016, 123, 884-897.	2.5	20
492	Ten years of anti-vascular endothelial growth factor therapy. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 385-403.	21.5	724
493	Correlation of 3-Dimensionally Quantified Intraretinal and Subretinal Fluid With Visual Acuity in Neovascular Age-Related Macular Degeneration. <i>JAMA Ophthalmology</i> , 2016, 134, 182.	1.4	80
494	First-Year Visual Acuity Outcomes of Providing Aflibercept According to the VIEW Study Protocol for Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2016, 123, 337-343.	2.5	85
495	Ranibizumab for the treatment of wet AMD: a summary of real-world studies. <i>Eye</i> , 2016, 30, 270-286.	1.1	106
496	Fit for the Eye: Aptamers in Ocular Disorders. <i>Nucleic Acid Therapeutics</i> , 2016, 26, 127-146.	2.0	103
497	Fluctuations in Pigment Epithelial Detachment and Retinal Fluid Using a Bimonthly Treatment Regimen with Aflibercept for Neovascular Age-Related Macular Degeneration. <i>Ophthalmologica</i> , 2016, 235, 42-48.	1.0	19
498	Screening for Impaired Visual Acuity in Older Adults. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 908.	3.8	32
499	Treatment for neovascular age related macular degeneration: The state of the art. <i>European Journal of Pharmacology</i> , 2016, 787, 78-83.	1.7	21
500	A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration. <i>British Journal of Ophthalmology</i> , 2016, 100, 914-917.	2.1	98
501	Retinal Pigment Epithelial Atrophy in Neovascular Age-Related Macular Degeneration After Ranibizumab Treatment. <i>American Journal of Ophthalmology</i> , 2016, 161, 94-103.e1.	1.7	36
502	A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. <i>Progress in Retinal and Eye Research</i> , 2016, 50, 1-24.	7.3	284
503	Change in vision after retinal pigment epithelium tear following the use of anti-VEGF therapy for age-related macular degeneration. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2016, 254, 1-6.	1.0	10
504	Predictors of 1-year visual outcome in OCT analysis comparing ranibizumab monotherapy versus combination therapy with PDT in exudative age-related macular degeneration. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 560-565.	1.0	9
505	Efficacy and safety of a fixed bimonthly ranibizumab treatment regimen in eyes with neovascular age-related macular degeneration: results from the RABIMO trial. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2017, 255, 923-934.	1.0	8

#	ARTICLE	IF	CITATIONS
506	Incidence and risk factors of retreatment after three-monthly aflibercept therapy for exudative age-related macular degeneration. <i>Scientific Reports</i> , 2017, 7, 44020.	1.6	21
507	Gene Therapy in Neovascular Age-related Macular Degeneration: Three-Year Follow-up of a Phase 1 Randomized Dose Escalation Trial. <i>American Journal of Ophthalmology</i> , 2017, 177, 150-158.	1.7	57
508	Choroidal Thickness and Visual Prognosis in Type 1 Lesion Due to Neovascular Age-Related Macular Degeneration. <i>European Journal of Ophthalmology</i> , 2017, 27, 196-200.	0.7	5
509	Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials. <i>BMC Ophthalmology</i> , 2017, 17, 7.	0.6	54
510	Targeting Vascular Endothelial Growth Factor. , 2017, , 99-139.		0
511	UK AMD/DR EMR REPORT IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice. <i>British Journal of Ophthalmology</i> , 2017, 101, 1683-1688.	2.1	37
512	A systematic review to assess the "treat-and-extend" dosing regimen for neovascular age-related macular degeneration using ranibizumab. <i>Eye</i> , 2017, 31, 1337-1344.	1.1	45
513	INTRAVITREAL AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH LIMITED RESPONSE TO RANIBIZUMAB. <i>Retina</i> , 2017, 37, 1185-1192.	1.0	11
514	LONG-TERM OUTCOMES AND INCIDENCE OF RECURRENCE OF NEOVASCULARIZATION IN TREATED EXUDATIVE AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2017, 37, 951-961.	1.0	22
517	Different Clinical Courses on Long-Term Follow-Up of Age-Related Macular Degeneration Patients Treated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections. <i>Ophthalmologica</i> , 2017, 238, 217-225.	1.0	13
518	Management of Large Submacular Hemorrhages Due to Exudative AMD Utilizing Pars Plana Vitrectomy, Subretinal Tissue Plasminogen Activator, and Gas Insertion Compared With Antivascular Endothelial Growth Factor Alone. <i>Journal of Vitreoretinal Diseases</i> , 2017, 1, 34-40.	0.2	3
519	NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH ADVANCED VISUAL LOSS TREATED WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. <i>Retina</i> , 2017, 37, 257-264.	1.0	5
520	Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2017, 255, 2127-2134.	1.0	25
521	Appropriateness of quality standards for meaningful intercentre comparisons of aflibercept service provision for neovascular age-related macular degeneration. <i>Eye</i> , 2017, 31, 1613-1620.	1.1	11
522	OUTCOMES OF AN INTRAVITREAL INJECTION CLINIC. <i>Retina</i> , 2017, 37, 1371-1376.	1.0	13
523	24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting. <i>BMC Ophthalmology</i> , 2017, 17, 58.	0.6	23
524	Neovascular age-related macular degeneration treated with ranibizumab or aflibercept in the same large clinical setting: visual outcome and number of injections. <i>Acta Ophthalmologica</i> , 2017, 95, 128-132.	0.6	19
525	Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2017, 255, 61-67.	1.0	4

#	ARTICLE	IF	CITATIONS
526	Factors Affecting Compliance to Intravitreal Anti-Vascular Endothelial Growth Factor Therapy in Patients with Age-Related Macular Degeneration. <i>Türk Oftalmoloji Dergisi</i> , 2017, 47, 205-210.	0.4	69
527	The VEGF Treatment of AMD Switch Study (The vTAS Study). <i>Asia-Pacific Journal of Ophthalmology</i> , 2017, 6, 481-487.	1.3	4
528	Automatic detection of the foveal center in optical coherence tomography. <i>Biomedical Optics Express</i> , 2017, 8, 5160.	1.5	26
529	Development of a Sustainable Release System for a Ranibizumab Biosimilar Using Poly(lactic-co-glycolic acid) Biodegradable Polymer-Based Microparticles as a Platform. <i>Biological and Pharmaceutical Bulletin</i> , 2017, 40, 145-150.	0.6	25
530	A Retrospective Analysis of the Real-Life Utilization of Ranibizumab in Patients with Wet Age-Related Macular Degeneration from Portugal. <i>Acta Medica Portuguesa</i> , 2017, 30, 449-456.	0.2	4
531	Combination verteporfin photodynamic therapy ranibizumab-dexamethasone in choroidal neovascularization due to age-related macular degeneration: results of a phase II randomized trial. <i>Clinical Ophthalmology</i> , 2017, Volume 11, 223-231.	0.9	13
532	Testing the clinical value of multifocal electroretinography and microperimetry and the effects of intravitreal therapy with ranibizumab on macular function in the course of wet age-related macular degeneration: a 1-year prospective study. <i>Clinical Ophthalmology</i> , 2017, Volume 11, 621-629.	0.9	7
534	Real-world Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration in the United States. <i>Ophthalmology Retina</i> , 2018, 2, 645-653.	1.2	63
535	Development of facile drug delivery platform of ranibizumab fabricated PLGA-PEGylated magnetic nanoparticles for age-related macular degeneration therapy. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2018, 183, 133-136.	1.7	24
536	Predicting Visual Acuity by Using Machine Learning in Patients Treated for Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2018, 125, 1028-1036.	2.5	88
537	The Real-World Effect of Intravitreal Anti-Vascular Endothelial Growth Factor Drugs on Intraocular Pressure. <i>Ophthalmology</i> , 2018, 125, 676-682.	2.5	53
539	Lid splinting eyelid retraction technique: a minimised sterile approach for intravitreal injections. <i>British Journal of Ophthalmology</i> , 2018, 102, 1254-1258.	2.1	9
540	Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. <i>Progress in Retinal and Eye Research</i> , 2018, 65, 127-146.	7.3	205
541	The Systemic Safety of Ranibizumab in Patients 85 Years and Older with Neovascular Age-Related Macular Degeneration. <i>Ophthalmology Retina</i> , 2018, 2, 667-675.	1.2	7
542	POOLED ESTIMATES OF INCIDENCE OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS WITH AND WITHOUT TOPICAL ANTIBIOTIC PROPHYLAXIS. <i>Retina</i> , 2018, 38, 01-11.	1.0	37
543	Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2018, 125, 57-65.	2.5	202
544	Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry. <i>Ophthalmology</i> , 2018, 125, 522-528.	2.5	111
545	Aflibercept for Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in Germany. <i>Ophthalmology Retina</i> , 2018, 2, 539-549.	1.2	54

#	ARTICLE	IF	CITATIONS
546	Outcome of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration in real-life setting. <i>British Journal of Ophthalmology</i> , 2018, 102, 959-965.	2.1	29
547	Evolving multidimensional pharmacological approaches to CNV therapy in AMD. <i>Current Eye Research</i> , 2018, 43, 147-154.	0.7	8
548	Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial. <i>British Journal of Ophthalmology</i> , 2018, 102, 460-464.	2.1	34
549	Il trattamento con farmaci intravitreali anti-VEGF in pazienti naïve in Italia. <i>Global & Regional Health Technology Assessment</i> , 2018, 2018, 228424031879390.	0.2	1
550	Systemic Safety of Ranibizumab for Neovascular Age-Related Macular Degeneration: Do Ophthalmologists Still Have to Sweat the Small Stuff?. <i>Ophthalmology Retina</i> , 2018, 2, 1085-1086.	1.2	0
551	Real-life experience of ranibizumab therapy for neovascular age-related macular degeneration from Turkey. <i>International Journal of Ophthalmology</i> , 2018, 11, 267-273.	0.5	4
552	Surgical Removal of Internal Limiting Membrane and Layering of AAV Vector on the Retina Under Air Enhances Gene Transfection in a Nonhuman Primate. , 2018, 59, 3574.		26
553	Facile synthetic Photoluminescent Graphene Quantum dots encapsulated β -cyclodextrin drug carrier system for the management of macular degeneration: Detailed analytical and biological investigations. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2018, 189, 244-249.	1.7	17
554	The outcomes of aflibercept therapy in patients with age-related macular degeneration resistant to bevacizumab or ranibizumab. <i>Journal of Current Ophthalmology</i> , 2018, 30, 337-342.	0.3	2
555	Morphological Predictive Features on Spectral-Domain Optical Coherence Tomography for Visual Outcomes in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab. <i>BioMed Research International</i> , 2018, 2018, 1-9.	0.9	3
556	Neovascular Age-Related Macular Degeneration: A Visual Acuity Model of Natural Disease Progression and Ranibizumab Treatment Effect. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 660-669.	1.3	8
557	Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials. <i>BMC Ophthalmology</i> , 2018, 18, 130.	0.6	38
558	Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan. <i>Scientific Reports</i> , 2018, 8, 7486.	1.6	7
559	14 Age-Related Macular Degeneration. , 2018, , .		0
560	Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, S3-S15.	0.5	89
562	Systemic Safety in Ranibizumab-Treated Patients with Neovascular Age-Related Macular Degeneration: A Patient-Level Pooled Analysis. <i>Ophthalmology Retina</i> , 2018, 2, 1087-1096.	1.2	11
563	Spectral Domain Optical Coherence Tomography Allows the Unification of Clinical Decision Making for the Evaluation of Choroidal Neovascularization Activity. <i>Ophthalmologica</i> , 2019, 241, 32-37.	1.0	4
564	Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 PHOENIX Study. <i>American Journal of Ophthalmology</i> , 2019, 197, 156-167.	1.7	116

#	ARTICLE	IF	CITATIONS
565	<p>Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration</p>. Clinical Ophthalmology, 2019, Volume 13, 1323-1329.	0.9	42
566	<p>Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration</p>. Clinical Ophthalmology, 2019, Volume 13, 1289-1295.	0.9	2
567	Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. The Cochrane Library, 2019, 2019, CD005139.	1.5	116
568	Effectiveness of monthly and fortnightly anti-VEGF treatments for age-related macular degeneration. Arquivos Brasileiros De Oftalmologia, 2019, 82, 225-232.	0.2	4
569	Thermo-responsive hydrogel as an anti-VEGF drug delivery system to inhibit retinal angiogenesis in Rex rabbits. Technology and Health Care, 2019, 27, 153-163.	0.5	17
570	Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-Related Macular Disease. Ophthalmology, 2019, 126, 841-848.	2.5	61
571	Feasibility of support vector machine learning in age-related macular degeneration using small sample yielding sparse optical coherence tomography data. Acta Ophthalmologica, 2019, 97, e719-e728.	0.6	10
572	Efficacy and safety of intravitreal drug injections using a short 34-gauge needle. Japanese Journal of Ophthalmology, 2019, 63, 269-275.	0.9	2
573	Intravenous injection of l-aspartic acid Î²-hydroxamate attenuates choroidal neovascularization via anti-VEGF and anti-inflammation. Experimental Eye Research, 2019, 182, 93-100.	1.2	6
574	Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review. BMJ Open Ophthalmology, 2019, 4, e000398.	0.8	85
575	Treat-and-extend regimens with anti-vascular endothelial growth factor agents in age-related macular degeneration. Expert Review of Ophthalmology, 2019, 14, 287-307.	0.3	2
576	Post-marketing dosing changes in the label of biologicals. British Journal of Clinical Pharmacology, 2019, 85, 715-721.	1.1	4
577	Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of on-demand therapy every 4 or 8 weeks. Acta Ophthalmologica, 2019, 97, 107-112.	0.6	11
579	Regenerative medicine as a novel strategy for AMD treatment: a review. Biomedical Physics and Engineering Express, 2020, 6, 012001.	0.6	2
580	HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology, 2020, 127, 72-84.	2.5	551
581	Brolucizumab: is extended VEGF suppression on the horizon?. Eye, 2020, 34, 424-426.	1.1	7
582	Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients. Ophthalmology Retina, 2020, 4, 19-30.	1.2	108
583	Real-World Treatment Outcomes of Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Asians. Ophthalmology Retina, 2020, 4, 403-414.	1.2	25

#	ARTICLE	IF	CITATIONS
584	Risk of Death Associated With Intravitreal Anti-VEGF Vascular Endothelial Growth Factor Therapy. JAMA Ophthalmology, 2020, 138, 50.	1.4	20
585	SUSPENDING TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN CASES OF FUTILITY. Retina, 2020, 40, 1010-1020.	1.0	8
586	Management Strategies and Visual Results for the Treatment of Neovascular Age-Related Macular Degeneration. , 2020, , .		1
587	Short-term outcomes of patients with neovascular exudative AMD: the effect of COVID-19 pandemic. Graefe's Archive for Clinical and Experimental Ophthalmology, 2020, 258, 2621-2628.	1.0	53
588	Six and eight weeks injection frequencies of bevacizumab are non-inferior to the current four weeks injection frequency for quality of life in neovascular age-related macular degeneration: a randomized controlled trial. Quality of Life Research, 2020, 29, 3305-3313.	1.5	2
589	Sustained suppression of VEGF for treatment of retinal/choroidal vascular diseases. Progress in Retinal and Eye Research, 2021, 83, 100921.	7.3	57
590	Extended intervals for wet AMD patients with high retreatment needs: informing the risk during COVID-19, data from real-world evidence. Eye, 2020, 35, 2793-2801.	1.1	16
591	Predictors of persistent disease activity following anti-VEGF loading dose for nAMD patients in Singapore: the DIALS study. BMC Ophthalmology, 2020, 20, 324.	0.6	3
592	The Impact of COVID-19 on Intravitreal Injection Compliance. SN Comprehensive Clinical Medicine, 2020, 2, 2546-2549.	0.3	40
593	Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches. International Journal of Molecular Sciences, 2020, 21, 8242.	1.8	82
594	Visual benefit versus visual gain: what is the effect of baseline covariants in the treatment arm relative to the control arm? A pooled analysis of ANCHOR and MARINA. British Journal of Ophthalmology, 2020, 104, 672-677.	2.1	14
595	Clinical outcomes of 1% PRN and 3% Q3M regimens of intravitreal conbercept injection for exudative age-related macular degeneration. Scientific Reports, 2020, 10, 8010.	1.6	4
596	Brolucizumab-key learnings from HAWK and HARRIER. Eye, 2020, 34, 1318-1320.	1.1	3
597	Aqueous humour proteins and treatment outcomes of anti-VEGF therapy in neovascular age-related macular degeneration. PLoS ONE, 2020, 15, e0229342.	1.1	4
598	Iatrogenic ophthalmic artery occlusion and retinal artery occlusion. Progress in Retinal and Eye Research, 2020, 78, 100848.	7.3	22
599	Providing a Safe and Effective Intravitreal Treatment Service: Strategies for Service Delivery. Clinical Ophthalmology, 2020, Volume 14, 1315-1328.	0.9	11
600	Eliminating Visual Acuity and Dilated Fundus Examinations Improves Cost Efficiency of Performing Optical Coherence Tomography-Guided Intravitreal Injections. American Journal of Ophthalmology, 2020, 219, 222-230.	1.7	14
601	Real-World Injection Frequency and Cost of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 253-266.	0.5	13

#	ARTICLE	IF	CITATIONS
602	Brolucizumab: an evolution in treatment for neovascular age-related macular degeneration. <i>Expert Review of Ophthalmology</i> , 2020, 15, 71-81.	0.3	0
603	Different concept injection strategies for the treatment of exudative age-related macular degeneration. <i>Medicine (United States)</i> , 2020, 99, e19007.	0.4	5
604	Comparison of the Efficacy of Brolucizumab with Natural Disease Progression in Wet AMD Using Clinical Data from the Phase III HAWK and HARRIER Trials and Modelled Placebo Data. <i>Current Eye Research</i> , 2020, 45, 1298-1301.	0.7	9
605	A systematic approach to evaluate practice-based process- and outcome data applied to the treatment of neovascular age-related macular degeneration. <i>BMC Ophthalmology</i> , 2020, 20, 21.	0.6	1
607	Twenty-four-month outcomes of inflammatory choroidal neovascularisation treated with intravitreal anti-vascular endothelial growth factors: a comparison between two treatment regimens. <i>British Journal of Ophthalmology</i> , 2020, 104, 1052-1056.	2.1	20
608	Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2020, 127, 1331-1344.	2.5	73
609	Neutralisation of adeno-associated virus transduction by human vitreous humour. <i>Gene Therapy</i> , 2021, 28, 242-255.	2.3	6
610	Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities. <i>Progress in Retinal and Eye Research</i> , 2021, 82, 100906.	7.3	133
611	Digital technology, tele-medicine and artificial intelligence in ophthalmology: A global perspective. <i>Progress in Retinal and Eye Research</i> , 2021, 82, 100900.	7.3	261
612	The Timing of Large Submacular Hemorrhage Secondary to Age-Related Macular Degeneration Relative to Anti-VEGF Therapy. <i>Ophthalmology Retina</i> , 2021, 5, 342-347.	1.2	6
613	Worth changing? Clinical effects of switching treatment in neovascular age-related macular degeneration from intravitreal ranibizumab and aflibercept to bevacizumab in a region in southern Sweden. <i>European Journal of Ophthalmology</i> , 2021, 31, 144-148.	0.7	0
614	The influence of delayed treatment due to COVID-19 on patients with neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232110263.	1.1	12
616	Predicting Incremental and Future Visual Change in Neovascular Age-Related Macular Degeneration Using Deep Learning. <i>Ophthalmology Retina</i> , 2021, 5, 1074-1084.	1.2	23
617	Comparative efficacy and safety of different regimens of ranibizumab for neovascular age-related macular degeneration: a network meta-analysis of randomised controlled trials. <i>BMJ Open</i> , 2021, 11, e040906.	0.8	3
618	Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration. <i>BMC Ophthalmology</i> , 2021, 21, 90.	0.6	6
619	Repurposing bortezomib for choroidal neovascularization treatment via antagonizing VEGF-A and PDGF-D mediated signaling. <i>Experimental Eye Research</i> , 2021, 204, 108446.	1.2	6
620	Aflibercept in real-life for the treatment of age-related macular degeneration using a treat and extend protocol: The Armada study. <i>European Journal of Ophthalmology</i> , 2022, 32, 356-363.	0.7	1
621	Five-Year Outcome of Aflibercept Monotherapy for Exudative Age-Related Macular Degeneration with Good Baseline Visual Acuity. <i>Journal of Clinical Medicine</i> , 2021, 10, 1098.	1.0	4

#	ARTICLE	IF	CITATIONS
622	Safety and efficacy of Razumab [®] (world's first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study. <i>International Journal of Retina and Vitreous</i> , 2021, 7, 24.	0.9	9
623	Importance of Anatomical Efficacy for Disease Control in Neovascular AMD: An Expert Opinion. <i>Ophthalmology and Therapy</i> , 2021, 10, 231-243.	1.0	1
624	Questionnaire to Assess Life Impact of Treatment by Intravitreal Injections (QUALITII): Development of a patient-reported measure to assess treatment burden of repeat intravitreal injections. <i>BMJ Open Ophthalmology</i> , 2021, 6, e000669.	0.8	9
625	PRN Treatment of Neovascular AMD with Cycles of Three Monthly Injections. <i>Journal of Ophthalmic and Vision Research</i> , 2021, 16, 178-186.	0.7	3
626	Thrombotic and bleeding risk of angiogenesis inhibitors in patients with and without malignancy. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1852-1863.	1.9	17
627	RETINAL FLUID AND THICKNESS AS MEASURES OF DISEASE ACTIVITY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2021, 41, 1579-1586.	1.0	24
628	A Baseline Score to Predict Response to Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration. <i>Translational Vision Science and Technology</i> , 2021, 10, 11.	1.1	7
629	Efficacy of anti-vascular endothelial growth factor agents for treating neovascular age-related macular degeneration in vitrectomized eyes. <i>PLoS ONE</i> , 2021, 16, e0252006.	1.1	2
630	Treat and extend paradigm in management of neovascular age-related macular degeneration: current practice and future directions. <i>Expert Review of Ophthalmology</i> , 2021, 16, 267-286.	0.3	0
631	Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 743-752.	0.5	9
632	Cardiovascular Adverse Events With Intravitreal Anti-Vascular Endothelial Growth Factor Drugs. <i>JAMA Ophthalmology</i> , 2021, 139, 610.	1.4	23
633	Long-Term Analysis of Clinical Features and Treatment Outcomes of Inflammatory Choroidal Neovascularization. <i>American Journal of Ophthalmology</i> , 2022, 233, 18-29.	1.7	5
634	Morphological characteristics of eyes with neovascular age-related macular degeneration and good long-term visual outcomes after anti-VEGF therapy. <i>British Journal of Ophthalmology</i> , 2023, 107, 399-405.	2.1	11
635	Complications Associated with Worse Visual Outcomes in Patients with Exudative Neovascular Age-Related Macular Degeneration. <i>Ophthalmologica</i> , 2021, 244, 512-522.	1.0	6
636	Topical Triamcinolone Acetonide-Loaded Liposome Formulation Used as an Adjuvant to Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration. <i>Pharmaceutics</i> , 2021, 13, 1491.	2.0	4
637	Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration. <i>JAMA Ophthalmology</i> , 2021, 139, 68.	1.4	50
638	Protein Drug Delivery and Formulation Development. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2011, , 409-448.	0.2	4
639	CONSEQUENCES OF LAPSES IN TREATMENT WITH VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN ROUTINE CLINICAL PRACTICE. <i>Retina</i> , 2021, 41, 581-587.	1.0	19

#	ARTICLE	IF	CITATIONS
640	INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH OR WITHOUT PRIOR TREATMENT WITH PHOTODYNAMIC THERAPY. <i>Retina</i> , 2010, 30, 85-92.	1.0	15
641	Effectiveness of ranibizumab intravitreal injections for exudative age-related macular degeneration treatment: 12-month outcomes. <i>Medical Science Monitor</i> , 2011, 17, CR485-CR490.	0.5	7
642	Effectiveness of Intravitreal Injection of Ranibizumab for Neovascular Age-Related Macular Degeneration with Serous Pigment Epithelial Detachment. <i>Medical Science Monitor</i> , 2016, 22, 833-839.	0.5	7
643	Transscleral Sustained Vasohibin-1 Delivery by a Novel Device Suppressed Experimentally-Induced Choroidal Neovascularization. <i>PLoS ONE</i> , 2013, 8, e58580.	1.1	23
644	IKK2 Inhibition Attenuates Laser-Induced Choroidal Neovascularization. <i>PLoS ONE</i> , 2014, 9, e87530.	1.1	24
646	Dosing regimens of angiogenesis inhibitors in the treatment of neovascular age-related macular degeneration patients. <i>Ophthalmology Journal</i> , 2019, 12, 47-56.	0.1	2
647	Ocular neovascular-related diseases: immunological mechanisms of development and the potential of anti-angiogenic therapy. <i>Ophthalmology Journal</i> , 2016, 9, 58-67.	0.1	6
648	Fixed bimonthly aflibercept in naïve and switched neovascular age-related macular degeneration patients: one year outcomes. <i>International Journal of Ophthalmology</i> , 2016, 9, 1156-62.	0.5	7
649	<p>Gene, Cell and Antibody-Based Therapies for the Treatment of Age-Related Macular Degeneration</p>. <i>Biologics: Targets and Therapy</i> , 2020, Volume 14, 83-94.	3.0	17
650	Evaluation of the Performance of an Ophthalmic Thermosensitive Hydrogel Containing Combination of Suramin and Bevacizumab. <i>Current Pharmaceutical Design</i> , 2017, 22, 6587-6594.	0.9	1
651	Pharmacokinetic and Pharmacodynamic Properties of Anti-VEGF Drugs After Intravitreal Injection. <i>Current Drug Metabolism</i> , 2015, 16, 572-584.	0.7	41
652	Clinical Risk Factors for Poor Anatomic Response to Ranibizumab in Neovascular Age-Related Macular Degeneration. <i>Open Ophthalmology Journal</i> , 2014, 8, 3-6.	0.1	9
653	Treat and Extend Dosing Regimen with Anti-vascular Endothelial Growth Factor Agents for Neovascular Age-related Macular Degeneration. <i>American Journal of Ophthalmic Clinical Trials</i> , 0, 1, 1.	0.0	10
654	A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN). <i>Health Technology Assessment</i> , 2015, 19, 1-298.	1.3	62
655	Bevacizumab for the Treatment of Pediatric Retinal and Choroidal Diseases. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2010, 41, 582-592.	0.4	27
656	16-Gy Low-Voltage X-ray Irradiation With Ranibizumab Therapy for AMD: 6-Month Safety and Functional Outcomes. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2011, 42, 468-473.	0.4	17
657	Angiographic Regression Patterns After Intravitreal Ranibizumab Injections for Neovascular Age-Related Macular Degeneration. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2011, 42, 498-508.	0.4	11
658	24-Gy Low-Voltage X-Ray Irradiation With Ranibizumab Therapy for Neovascular AMD: 6-Month Safety and Functional Outcomes. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2012, 43, 20-24.	0.4	17

#	ARTICLE	IF	CITATIONS
659	Ocular Hypertension and Intraocular Pressure Asymmetry After Intravitreal Injection of Anti-Vascular Endothelial Growth Factor Agents. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2013, 44, 460-464.	0.4	34
660	Meta-Analysis of Infectious Endophthalmitis After Intravitreal Injection of Anti-Vascular Endothelial Growth Factor Agents. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2014, 45, 143-149.	0.4	173
661	Clinical Monitoring of Patients With Age-Related Macular Degeneration Treated With Intravitreal Bevacizumab or Ranibizumab. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2014, 45, 285-291.	0.4	11
662	Improved Repeatability of Retinal Thickness Measurements Using Line-Scan Ophthalmoscope Image-Based Retinal Tracking. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2015, 46, 310-314.	0.4	6
663	36-Month Evaluation of Intravitreal Aflibercept Injection for Wet Age-Related Macular Degeneration in Patients Previously Treated With Ranibizumab or Bevacizumab. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2018, 49, 179-185.	0.4	2
664	Innovation in Neovascular Age-Related Macular Degeneration: Consideration of Brolucizumab, Abicipar, and the Port Delivery System. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2018, 49, 913-917.	0.4	11
665	Morphological changes in spectral domain optical coherence tomography guided bevacizumab injections in wet age-related macular degeneration, 12-months results. <i>Indian Journal of Ophthalmology</i> , 2014, 62, 554.	0.5	5
666	Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab. <i>Indian Journal of Ophthalmology</i> , 2015, 63, 832.	0.5	8
667	Management of neovascular Age-related macular degeneration: A review on landmark randomized controlled trials. <i>Middle East African Journal of Ophthalmology</i> , 2016, 23, 27.	0.5	24
668	Effect of a Single-Dose Regimen of Intravitreal Ranibizumab in the Treatment of Neovascular Age-Related Macular Degeneration. <i>Journal of Clinical & Experimental Ophthalmology</i> , 2012, 03, .	0.1	4
669	Increased Visual Acuity Will Not Necessarily Equal an Increased Reading Ability in Patients with Subfoveal Neovascular Macular Degeneration. <i>International Journal of Clinical Medicine</i> , 2011, 02, 404-410.	0.1	2
670	One-Year Results of Aflibercept in Vascularized Pigment Epithelium Detachment due to Neovascular AMD: A Prospective Study. <i>European Journal of Ophthalmology</i> , 2017, 27, 74-79.	0.7	9
671	Switching from Intravitreal Ranibizumab to Bevacizumab for Age-Related Macular Degeneration. <i>ISRN Ophthalmology</i> , 2011, 2011, 1-4.	1.7	2
672	Therapeutic Modalities of Exudative Age-related Macular Degeneration. <i>Medicinski Arhiv = Medical Archives = Archives De Médecine</i> , 2014, 68, 204.	0.4	10
673	Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes. <i>British Journal of Ophthalmology</i> , 2023, 107, 384-391.	2.1	15
674	Anti-VEGF and Other Novel Therapies for Neovascular Age-Related Macular Degeneration: An Update. <i>BioDrugs</i> , 2021, 35, 673-692.	2.2	19
675	Neue Arzneimittel 2007. , 2008, , 47-118.		0
677	Tratamiento combinado farmacológico en la DMAE exudativa: Más allá de la monoterapia antiangiogénica. , 2010, , 173-180.		0

#	ARTICLE	IF	CITATIONS
678	çœ¼4â°•ã©ç—...æ°—. Juntendo, Igaku, 2010, 56, 224-227.	0.1	0
679	Principales ensayos clínicos con fármacos anti-VEGF en la DMAE exudativa. , 2010, , 7-14.		0
680	Pautas de seguimiento y retratamiento en pacientes con degeneración macular tratados con ranibizumab (Lucentis®). , 2010, , 15-23.		0
681	Tomografía de coherencia óptica en el seguimiento del tratamiento anti-VEGF. , 2010, , 39-48.		0
682	Combination Therapy with Ocular Photodynamic Therapy for Age-Related Macular Degeneration. , 2011, , 99-118.		0
683	Anti-VEGF-Therapie der AMD: Ergebnisse und Leitlinien. , 2011, , 237-251.		0
684	Re-Treatment Strategies for Neovascular AMD: When to Treat? When to Stop?. , 0, , .		0
685	Combined Therapies to Treat CNV in AMD: PDT + Anti-VEGF. , 0, , .		0
686	To Compare Photodynamic Therapy with Ranibizumab vs Photodynamic Therapy with Pegaptanib for Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration. World Journal of Retina and Vitreous, 2012, 2, 23-27.	0.0	0
687	The Frequency of the Nonresponsiveness to Intravitreal Injection of the Anti-Vascular Endothelial Growth Factor Agent in Neovascular Age Related Macular Degeneration. International Journal of Ophthalmic Pathology, 2013, 02, .	0.1	1
688	Modalidades de Tratamiento de la Degeneración Macular Asociada a la Edad. Highlights of Ophthalmology, 2013, 41, 2-4.	0.0	0
689	Neovascular Age-Related Macular Degeneration: Rationale for Current Treatment Guidelines. Essentials in Ophthalmology, 2013, , 107-125.	0.0	0
690	Reliable Therapeutic Modalities To Treat Age-Related Macular Degeneration. Highlights of Ophthalmology, 2013, 41, 2-4.	0.0	0
691	Prise en charge de la DMLA exudative en 2013. Bulletin De L'Academie Nationale De Medecine, 2013, 197, 1339-1346.	0.0	0
692	Vascular Endothelial Growth Factors: Pharmacological aspects and applications in ophthalmic practices. Delhi Journal of Ophthalmology, 2013, 24, 88-92.	0.0	0
693	Imagerie de la dégénérescence maculaire exsudative. , 2014, , 269-285.		0
694	Results of Lucentis use as a routine practice in wet age-related macular degeneration patients. Ophthalmology Journal, 2014, 7, 47-57.	0.1	1
695	Age-related macular degeneration treatment: current view (literature review). Medicinos Teorija Ir Praktika, 2014, 21, 43-50.	0.0	1

#	ARTICLE	IF	CITATIONS
696	Bevacizumab in age-related macular degeneration – comparison of subjective estimation of vision with objective test results. <i>Annales Academiae Medicae Silesiensis</i> , 2015, 69, 33-41.	0.1	0
699	Bevacizumab for neovascular age-related macular degeneration in Chinese patients in a clinical setting. <i>International Journal of Ophthalmology</i> , 2016, 9, 424-30.	0.5	0
700	Factors Associated With Poor Response to Aflibercept After Switching From Ranibizumab or Bevacizumab in Neovascular Age-related Macular Degeneration. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2016, 47, 458-465.	0.4	3
701	ANTISEPTICS AT INTRAVITREAL INJECTIONS. <i>Biulleten' Vostochno-Sibirskogo Nauchnogo Tsentra</i> , 2016, 1, 55-59.	0.1	0
702	Our experience in visual functions' improvement in patients with age-related macular degeneration at switching from one anti-VEGF agent to another. <i>Ophthalmology Journal</i> , 2017, 10, 67-73.	0.1	1
703	Traitement de la dégénérescence maculaire liée à l'âge. , 2018, , 1025-1035.e1.		0
705	Principles of anti-VEGF dosing in the treatment of neovascular age-related macular degeneration. <i>Rossiiskii Oftal'mologicheskii Zhurnal</i> , 2019, 12, 102-112.	0.1	0
706	Quarterly Anti-Vascular Endothelial Growth Factor Dosing for Neovascular Age-Related Macular Degeneration: Real-World Clinical Outcomes. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2019, 50, e250-e256.	0.4	1
708	Health Promotion, Audit, Research and Evidence-Based Medicine. , 2020, , 189-220.		0
710	Management Strategies for Neovascular AMD. , 2020, , 99-108.		0
711	MANAGEMENT OF RETINAL PIGMENT EPITHELIUM TEAR DURING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. <i>Retina</i> , 2021, 41, 671-678.	1.0	6
712	Neovascular AMD. <i>Retina Atlas</i> , 2020, , 13-28.	0.0	0
714	Characterization of Antineovascularization Activity and Ocular Pharmacokinetics of Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GNE-947. <i>Drug Metabolism and Disposition</i> , 2020, 48, 408-419.	1.7	5
715	CLINICAL OUTCOMES AND TREATMENT COURSE OF EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION FOLLOWING THE DEVELOPMENT OF ENDOPHTHALMITIS. <i>Retina</i> , 2021, 41, 1242-1250.	1.0	5
716	In vivo imaging of choroidal angiogenesis using fluorescence-labeled cationic liposomes. <i>Molecular Vision</i> , 2012, 18, 1045-54.	1.1	15
717	Low-fluence photodynamic therapy combinations in the treatment of exudative age-related macular degeneration. <i>International Journal of Ophthalmology</i> , 2012, 5, 377-83.	0.5	1
718	Quantifying the increasing use of anti-vascular endothelial growth factor therapy in ophthalmology. <i>McGill Journal of Medicine</i> , 2011, 13, 38.	0.1	3
719	Vascular endothelial growth factors and their inhibitors in ocular neovascular disorders. <i>Journal of Ophthalmic and Vision Research</i> , 2009, 4, 105-14.	0.7	12

#	ARTICLE	IF	CITATIONS
720	Temporal pattern of resolution/recurrence of choroidal neovascularization during bevacizumab therapy for wet age-related macular degeneration. <i>International Journal of Ophthalmology</i> , 2013, 6, 600-5.	0.5	7
721	Age-related macular degeneration: beyond anti-angiogenesis. <i>Molecular Vision</i> , 2014, 20, 46-55.	1.1	26
722	Optical Coherence Tomography Monitoring Strategies for A-VEGF-Treated Age-Related Macular Degeneration: An Evidence-Based Analysis. <i>Ontario Health Technology Assessment Series</i> , 2014, 14, 1-64.	3.0	8
723	Age-related macular degeneration: anti-vascular endothelial growth factor treatment. <i>Clinical Evidence</i> , 2016, 2016, .	0.2	6
724	TENAYA and LUCERNE. <i>Ophthalmology Science</i> , 2021, 1, 100076.	1.0	24
725	Effect of Anti-VEGF Therapy on the Disease Progression of Neovascular Age-Related Macular Degeneration: A Systematic Review and Model-Based Meta-Analysis. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 594-608.	1.0	4
726	The 12- and 24-Month Effects of Intravitreal Ranibizumab, Aflibercept, and Bevacizumab on Intraocular Pressure. <i>Ophthalmology</i> , 2022, 129, 498-508.	2.5	8
727	Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. <i>Lancet, The</i> , 2022, 399, 729-740.	6.3	190
728	Managing Neovascular Age-Related Macular Degeneration in Clinical Practice: Systematic Review, Meta-Analysis, and Meta-Regression. <i>Journal of Clinical Medicine</i> , 2022, 11, 325.	1.0	13
729	Intravitreal anti-VEGF agents – The way forward. , 0, 1, 2-4.		0
730	Anti-VEGF Drugs Dynamics: Relevance for Clinical Practice. <i>Pharmaceutics</i> , 2022, 14, 265.	2.0	7
731	On label bevacizumab for retina: where it stands. <i>Eye</i> , 2022, 36, 916-917.	1.1	5
732	Novel approach to antiangiogenic factors in age-related macular degeneration therapy. <i>Central-European Journal of Immunology</i> , 0, , .	0.4	0
733	Evaluating an automated machine learning model that predicts visual acuity outcomes in patients with neovascular age-related macular degeneration. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2022, , 1.	1.0	7
734	Efficacy and Safety of Antivasular Endothelial Growth Factor (Anti-VEGF) in Treating Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Meta-analysis. <i>Journal of Immunology Research</i> , 2022, 2022, 1-11.	0.9	3
737	The NEI VFQ-25C: Calibrating Items in the National Eye Institute Visual Function Questionnaire-25 to Enable Comparison of Outcome Measures. <i>Translational Vision Science and Technology</i> , 2022, 11, 10.	1.1	8
738	Common retinal disorders. , 2013, , 413-432.		0
740	Screening for Impaired Visual Acuity in Older Adults. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 2129.	3.8	10

#	ARTICLE	IF	CITATIONS
741	From Bench to Bedside: Faricimab Enters the Clinic. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2022, 53, 305-309.	0.4	1
742	Characterizing early residual fluid in neovascular age-related macular degeneration using machine learning in routine clinical practice. <i>Ophthalmology Retina</i> , 2022, , .	1.2	0
743	Angiogenic footprints in diabetic retinopathy: opportunities for drug development. <i>Biotechnology and Genetic Engineering Reviews</i> , 2023, 39, 118-142.	2.4	5
746	Long-Term Consequences of COVID-19 Lockdown in Neovascular AMD Patients in Spain: Structural and Functional Outcomes after 1 Year of Standard Follow-Up and Treatment. <i>Journal of Clinical Medicine</i> , 2022, 11, 5063.	1.0	2
748	Relationship between ganglion cell complex thickness and vision in age-related macular degeneration treated with aflibercept. <i>European Journal of Ophthalmology</i> , 0, , 112067212211490.	0.7	1
751	The Effect of Intravitreal Bevacizumab Injection in Wet Age-Related Macular Degeneration Patients with Cataract Surgery. <i>Keimyung Medical Journal</i> , 0, , .	0.1	0
752	Common retinal disorders. , 2018, , 413-435.		0
753	Ocular Delivery of Therapeutic Agents by Cell-Penetrating Peptides. <i>Cells</i> , 2023, 12, 1071.	1.8	8
754	Biosimilar versus Innovator Molecule of Ranibizumab in Neovascular Age-Related Macular Degeneration (The BALANCE Trial): Real-World Evidence. <i>Clinical Ophthalmology</i> , 0, Volume 17, 1067-1076.	0.9	4
755	Topical bromfenac as adjunctive treatment with intravitreal ranibizumab for diabetic macular edema. <i>International Ophthalmology</i> , 2023, 43, 3219-3226.	0.6	0
756	A model-based approach for historical borrowing, with an application to neovascular age-related macular degeneration. <i>Statistical Methods in Medical Research</i> , 2023, 32, 1064-1081.	0.7	0
764	Choroidal Neovascularization: Pathogenesis, Diagnosis, and Current Management Strategies. , 2023, , 217-244.		0